



Article Progesterone Receptor Modulates Extraembryonic Mesoderm and Cardiac Progenitor Specification during Mouse Gastrulation

Anna Maria Drozd¹, Luca Mariani^{1,†}, Xiaogang Guo^{1,†}, Victor Goitea², Niels Alvaro Menezes¹ and Elisabetta Ferretti^{1,*}

- ¹ Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, 2200 Copenhagen, Denmark
- ² Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense, Denmark
- * Correspondence: elisabetta.ferretti@sund.ku.dk
- † These authors contributed equally to this work.

Abstract: Progesterone treatment is commonly employed to promote and support pregnancy. While maternal tissues are the main progesterone targets in humans and mice, its receptor (PGR) is expressed in the murine embryo, questioning its function during embryonic development. Progesterone has been previously associated with murine blastocyst development. Whether it contributes to lineage specification is largely unknown. Gastrulation initiates lineage specification and generation of the progenitors contributing to all organs. Cells passing through the primitive streak (PS) will give rise to the mesoderm and endoderm. Cells emerging posteriorly will form the extraembryonic mesodermal tissues supporting embryonic growth. Cells arising anteriorly will contribute to the embryonic heart in two sets of distinct progenitors, first (FHF) and second heart field (SHF). We found that PGR is expressed in a posterior-anterior gradient in the PS of gastrulating embryos. We established in vitro differentiation systems inducing posterior (extraembryonic) and anterior (cardiac) mesoderm to unravel PGR function. We discovered that PGR specifically modulates extraembryonic and cardiac mesoderm. Overexpression experiments revealed that PGR safeguards cardiac differentiation, blocking premature SHF progenitor specification and sustaining the FHF progenitor pool. This role of PGR in heart development indicates that progesterone administration should be closely monitored in potential early-pregnancy patients undergoing infertility treatment.

Keywords: progesterone receptor; cardiac differentiation; mesoderm induction; mouse gastrulation; epiblast stem cells; extraembryonic mesoderm; cell adhesion; ECM

1. Introduction

One of the leading causes of recurring early pregnancy loss is embryo implantation failure and consequent embryonic death [1]. Hormonal treatment such as progesterone is frequently used to stimulate and support pregnancy, with maternal tissues being its primary target [2]. Progesterone signaling is evolutionarily conserved in mammals, and progesterone receptor (PGR) was shown to support functions of the adult organs such as the brain and heart [3–5]. While addressing its function in human embryo is impossible for ethical reasons, in mice, PGR is expressed in the gastrulating embryo, raising questions about its function during embryonic development.

Furthermore, progesterone is also associated with early murine embryonic development, as low progesterone concentrations lead to the developmental delay of blastocysts in vitro [6]. Following implantation, gastrulation represents a key step in embryonic life. In mammals, gastrulation is marked by a dynamic and transient population of cells located in a region called the primitive streak (PS), which gives rise to the mesoderm and the definitive endoderm [7–9]. Cells migrating out of the posterior end of the PS, corresponding to the



Citation: Drozd, A.M.; Mariani, L.; Guo, X.; Goitea, V.; Menezes, N.A.; Ferretti, E. Progesterone Receptor Modulates Extraembryonic Mesoderm and Cardiac Progenitor Specification during Mouse Gastrulation. *Int. J. Mol. Sci.* **2022**, *23*, 10307. https://doi.org/10.3390/ ijms231810307

Academic Editor: J. Carlos Villaescusa

Received: 8 August 2022 Accepted: 31 August 2022 Published: 7 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). posterior proximal end of the embryo, form the extraembryonic mesoderm that supports embryonic growth [7,9]. Extraembryonic mesoderm will give rise to the allantois, amnion, primitive hematopoietic cells, and the yolk sac. Conversely, cells emerging from the anterior PS will generate the embryonic mesoderm and definitive endoderm. The mesoderm will contribute to essential organs such as the heart, facial and skeletal muscles, bones, gonads, and kidneys, while the endoderm forms the pancreas, lungs, liver, and gut [8,9].

Whether progesterone could have a dual role in supporting maternal tissues and embryonic development at gastrulation is unknown. We found that PGR is expressed in a posterior–anterior gradient in the PS of gastrulating murine embryos, resembling the BMP signaling gradient. We established in vitro cell culture systems to model gastrulation and assessed the role of PGR in post-implantation cells. We employed mouse epiblast stem cells (EpiSCs) that correspond to the undifferentiated epiblast of post-implantation embryos and are primed to differentiate in vitro into different germ layer lineages [10,11]. To simulate the spatial allocation, we used various combinations of signaling cues that recapitulate the environment present in the embryo at gastrulation, mimicking the anterior (APS) and posterior (PPS) regions of the PS [12], and employed scRNA-Seq analyses to assess differentiation efficiency.

We found that PGR is expressed in EpiSCs and demonstrated that it is involved in early mesoderm specification, modulating extraembryonic and cardiac mesoderm differentiation. Furthermore, we show that PGR has a specific effect on the maturation of the PS-derived progenitors, promoting the differentiation of the BMP-responding cell populations and thus favoring the posterior mesoderm progenitors such as extraembryonic mesoderm and first heart field. We also report that during differentiation, progesterone signaling differentially modulates the expression of actin cytoskeleton remodeling, focal adhesion, and cell motility proteins implicated in the process of mesoderm formation.

In conclusion, we demonstrate that PGR plays a role in the early specification of extraembryonic mesoderm and cardiac progenitors at gastrulation. Given progesterone is used as a treatment for recurring early miscarriages and improved in vitro fertilization (IVF) success rate, the offspring of patients undergoing infertility treatment should be monitored with special emphasis on cardiovascular conditions.

2. Results

2.1. The Nuclear Receptor PGR Is Expressed in Primed Pluripotent Cells

Primed pluripotency is the state that immediately precedes germ layer specification, including PS induction and mesoderm differentiation [13,14]. We speculate that transcription factors (TFs) supporting the primed state could be important for setting up epiblast for early lineage commitment, biasing the choice towards specific cell lineages and cell types, such as the mesoderm progenitors. We also hypothesized that these TFs should be expressed in the early stage of PS induction and will play a subsequent role in early germ layer specification. The plasticity of epiblast cells ingressing at the PS is progressively restricted by BMP/TGF-beta/WNT signaling (Figure 1A,B) [14,15]. To simulate the spatial allocation, we use different combinations of signaling cues to recapitulate the environment present in the embryos at gastrulation time, mimicking the anterior (APS) and posterior (PPS) regions of the PS (Figure 1C). RNA-Seq profiling shows that PPS cells are enriched in posterior streak markers, *Evx1*, *Bmp4*, *Hand1*, *Tbx3*, *Foxf1*, and *Pgr*, demonstrating that a high level of BMP restricts the fate of PPS towards posterior and extraembryonic mesoderm, while the anterior markers Gsc, Sox17, Mesp1, Tbx6, Eomes, and Foxa2 are more abundant in the APS cells, suggesting that this population is enriched in progenitor cells with endoderm, cardiac, and paraxial mesoderm signatures.

To uncover TFs influencing the differentiation potential of primed pluripotent cells, we compare the transcriptional profiles of EpiSCs and mESCs cultured in either 2i/Lif or serum/Lif and identify 19 TFs enriched in EpiSCs (Figure 1D) [14]. After evaluating the known knockout phenotypes and functions of the short-listed genes, we narrowed the list down to six candidates (*Bcl11b*, *Pgr*, *Tshz1*, *Zfp521*, *Prox1*, and *Zfhx4*) (Figure 1E and

Supplementary Table S1). The expression analysis during PS induction and differentiation towards mesoderm-specific lineages (extraembryonic, lateral, and paraxial mesoderm) highlighted that two TFs are upregulated in PS: *Pgr* and *Bcl11b* (Figure 1E), suggesting their involvement in priming EpiSCs towards mesodermal or endodermal cell fate. Interestingly, progesterone receptor encoded by the *Pgr* gene is historically studied in the context of breast cancer, endometriosis, and embryo implantation [16–20]. However, our in vitro expression data suggests a novel function in the post-implantation epiblast during mesoderm specification. By comparing the expression pattern observed in vitro with the published scRNA-Seq data of gastrulating mouse embryos [21], we found that *Pgr* is expressed in the epiblast, PS, and mesoderm in vivo (Figure 1F). These data resemble the expression patterns we observe with the in vitro cell culture systems.



Figure 1. Cont.



Figure 1. Identification of PGR as a TF candidate involved in priming EpiSCs towards mesoderm fate. (A) Schematic representation of E6.5–7.0 gastrulating mouse embryo. Epiblast cells (yellow) ingress and become the posterior (PPS, light red) and/or anterior (APS, grey) primitive streak (PS). Cells originating in different regions of the PS display distinct mesodermal fate bias. Extraembryonic mesoderm (dark red) including blood (hemangioblast) and allantois originate from PPS, while APS will give rise to cardiac mesoderm (green), paraxial mesoderm (blue), and definitive endoderm (pink). The coordinated activity of different signaling pathways (NODAL, WNT, and BMP) activate specific transcriptional programs that direct mesodermal fate. (B) Illustration summarizing the protocol used to differentiate EpiSCs towards PPS and APS cells and their derivatives, cardiac mesoderm (CM) and paraxial mesoderm (PM) progenitors. (C) Heatmap of RNA-Seq of EpiSCs, PPS, and APS delineating the antero-posterior identity of the in vitro-generated cell populations. PPS cells are enriched in extraembryonic markers and known BMP target genes (Evx1, Bmp4, Hand1, Foxf1, and Tbx3), while APS cells show high levels of anterior PS markers (Gsc, Sox17, Tbx6, Eomes, and Foxa2). (D) Identification of 19 TFs specifically enriched in EpiSCs by comparing RNA-Seq data of EpiSCs with mouse ESCs cultured in 2i/LIF and serum/LIF. (E) Heatmap showing the expression of the six short-listed TFs in different cell types. *Blc11b* and *Pgr* exhibit a distinct pattern of expression, with the highest levels of mRNA found in EpiSCs, PPS, and APS (highlighted by arrows), (RNA-Seq, $p \le 0.05$, fold-change \geq 1.5). ESC, embryonic stem cells; EpiSC, epiblast stem cells; PPS, posterior primitive streak; APS, anterior primitive streak; ExM, extraembryonic mesoderm; CM, cardiac mesoderm; PM, paraxial mesoderm. (F) UMAP visualization and clustering of scRNA-Seq of gastrulating mouse embryos showing Pgr expression in the epiblast (yellow circle) and mesoderm (brown circle) (data set obtained from Pijuan-Sala et al. Nature 2019 [21]).

2.2. PGR Is Expressed in the Primitive Streak with a Posterior-to-Anterior Gradient

To further characterize *Pgr* function during gastrulation, we assess PGR protein levels and localization in embryonic day (E) 6.0-6.5 mouse embryos. PS formation represents the initiation of gastrulation, the process in which ectoderm, mesoderm, and endoderm cell fates are established [7,8]. The time and location of cells emerging from the PS are linked with subsequent cell identity, with extraembryonic mesoderm originating from the PPS, while cardiac mesoderm, paraxial mesoderm, and definitive endoderm cells arise from the APS (Figure 2A). Immunofluorescence (IF) shows that PGR is present at high levels in the PPS (Figure 2B, panels I–II), with a lower amount in APS (Figure 2B, panel II), and strikingly, absent in the anterior region of the gastrulating E6.75 embryo (Figure 2B, panel III). The embryo is co-stained with antibodies against SOX2 and T-BRA to identify the epiblast and the PS, respectively [22]. These data support the hypothesis that PGR plays a role in PS induction and potentially in mesoderm formation. Next, we employ mouse EpiSCs as cell culture model and analyze PGR levels during in vitro differentiation. Western blotting reveals higher levels of PGR in the PPS compared with the EpiSCs and mesoderm progenitors, extraembryonic mesoderm, and cardiac and paraxial mesoderm (Figure 2C), suggesting a correlation between PGR protein expression in vitro and in vivo. PGR is a nuclear receptor that translocates from the cytoplasm to the nucleus upon ligand binding and acts as a TF to either activate or repress the expression of its target genes [23,24]. However, ligand-bound PGR also has cytoplasmatic functions. Therefore, we use IF to pinpoint the cellular localization of PGR in EpiSCs and PPS. As shown in Figure 2E, the levels of PGR are higher in PPS, with a strong signal indicating cytoplasmatic localization. However, a small proportion of the receptor is found in the cell nucleus, indicating that it could also exert its function directly as a TF. By comparing *Pgr* expression among different lineages, we confirm that *Pgr* is highly expressed in PPS compared with definitive endoderm and neural lineages (Figure 2F). Significantly, RT-qPCR reveals that *Pgr* expression peaks at 18–24 h after inducing PS, which corresponds to a high expression of *T-Bra*, the hallmark PS marker (Figure 2F) [22,25]. We therefore show that the expression pattern of PGR in vitro corresponds to the one we report in vivo.



Figure 2. *Pgr* is expressed in primitive streak cells in vivo and in vitro. (**A**) Illustration depicting E6.5-E7.0 gastrulating embryo and indicating posterior primitive streak (PPS), anterior primitive streak (APS), and their derivatives. Endoderm (pink), primitive streak (red), epiblast (yellow), paraxial mesoderm (blue), cardiac mesoderm (green), and extraembryonic mesoderm (dark red). (**B**) Confocal images of E6.75 embryos probed with T-BRA (red), SOX2 (magenta) and PGR (green) antibodies reveal a gradient of PGR with higher levels in PPS. Panel I shows high levels of PGR in the PPS, panel I demonstrates low levels of PGR in the APS, while in panel III the complete absence of PGR in the most anterior part of the embryo. The schematic on the right depicts the PGR gradient (green) in the posterior and anterior PS. Images were taken using $40 \times$ objective. (**C**) Western blot assay confirming that PGR protein levels follow the same pattern as mRNA during mesoderm induction, with the highest protein concentration in PPS cells compared with EpiSCs, APS, ExM, CM, and PM. Histone H3 (H3) is used as loading control. (**D**) Illustration depicting the dual PGR activity as a ligand-dependent TF (nuclear localization) and modulator of signaling pathways (cytoplasmatic localization) with the previously described interaction with c-SRC [24]. (**E**) Immunofluorescence showing PGR localization in EpiSCs and PPS. In the EpiSCs, low levels of PGR are detected. In PPS,

PGR protein is localized mainly in the cytoplasm with a smaller percentage present in the nucleus. Images were taken using $63 \times$ objective. (F) RT-qPCR analysis of *Pgr* expression across different cell lineages. *Pgr* transcript is specifically expressed in EpiSCs and PPS. Time course induction of PPS shows the highest expression at 18 h of differentiation.

2.3. PGR Modulates the Differentiation of the Posterior Primitive Streak and *Extraembryonic Mesoderm*

Considering the unique expression pattern of *Pgr* in vivo and in vitro, we address its role in the specification of the PPS and its derivative, the extraembryonic mesoderm [26]. We first established a protocol generating PPS starting from EpiSCs and subsequently differentiated PPS towards the extraembryonic mesoderm (Figure 3A). Using bulk RNA-Seq, we profiled the extraembryonic mesoderm. These data confirm that the differentiation protocol recapitulates the expression pattern observed in the mouse embryo (Figure 3B). A further characterization by scRNA-Seq reveals that the PPS is a homogeneous cell population expressing the posterior markers Evx1, Hand1, Foxf1, and Col1A1 (Figure 3C and Supplementary Figure S1A,B). Similarly, scRNA-Seq analysis of extraembryonic mesoderm reveals a homogeneous distribution of the ExM markers Hand1, Igfr2, Bmp4, and Foxf1 [27,28] (Figure 3D and Supplementary Figure S1C–F). These data demonstrate the efficiency of the extraembryonic mesoderm differentiation protocol. We next generate EpiSC lines lacking Pgr via CRISPR-mediated knock-in of a hygromycin resistance cassette. This approach produces a truncated *Pgr* mRNA that is subsequently degraded (Supplementary Figure S2A). The Pgr Knockout clones (Pgr-KO) are screened by PCR genotyping, and the lack of the receptor protein is confirmed by Western blot (Supplementary Figure S2B,C). We identified at least three clones lacking Pgr expression with one allele with successful integration of the hygromycin cassette and one with CRISPR-induced frameshift that generates multiple premature stop codons (Supplementary Figure S2C). To confirm this, similarly to the WT cells, these mutated clones maintain their pluripotent and post-implantation epiblast characteristics, we assessed the expression of the pluripotency and epiblast markers such as Oct4, Sox2, Nanog, and Otx2 [29] (Supplementary Figure S2E).



Figure 3. Cont.



Figure 3. *Pgr* modulates PPS induction and extraembryonic mesoderm (ExM) formation. (**A**) Schematic illustration of the extraembryonic differentiation protocol. EpiSCs are initially subjected to PPS induction, and thereafter exposed to BMP for additional 24 h to induce ExM differentiation. High levels of BMP restrict PS cells towards extraembryonic mesoderm-like fate. (**B**) Heatmap displaying relative expression of selected differentially regulated genes in EpiSCs, PPS, and ExM (RNA-Seq, $p \le 0.05$, fold-change ≥ 1.5). (**C**) UMAP plots showing gene expression distribution in PPS cells. Individual cells are colored by expression of key posterior primitive streak markers (*T-Bra, Exv1*, and *Hand1*). (**D**) UMAP plots showing gene expression distribution in ExM. Individual cells are colored by the expression of key extraembryonic mesoderm marker genes (*Hand1, Foxf1*, and *Igrf2*). (**E**) Differential expression analysis of WT and *Pgr-KO* EpiSCs differentiated towards PPS and ExM revealing downregulation of PPS markers (*Hand1, Col1a1*, and *Bmp2*) and a stronger effect in ExM (*Hand1, Foxf1, Pecam1, Flk1*, and *Bmp4*). Upregulation of *Tal1, Gata2*, and *Sox17* in *Pgr-KO* indicates a shift of ExM towards a hemangioblast fate (RNA-Seq, $p \le 0.05$, fold-change ≥ 1.5).

Next, we differentiate WT and *Pgr-KO* EpiSCs towards PPS and extraembryonic mesoderm. In PPS, the extraembryonic signatures, connected to BMP signaling, *Bmp2*, *Bmp4*, and *Hand1*, are strongly affected, while other PPS markers, *T-Bra*, *Mixl1*, and *Evx1*, are slightly influenced (Figure 3E). The ExM markers *Foxf1*, *Bmp4*, and *Hand1* [27,28,30,31], are strongly downregulated due to *Pgr* inactivation (Figure 3E), suggesting that extraembryonic mesoderm formation is affected in *Pgr-KO*. Conversely, the upregulation of *Tal1* and *Gata2* could indicate a shift of *Pgr-KO* extraembryonic mesoderm cells towards hemangioblast fate [31,32]. *Foxf1* and *Pitx1* are markers of allantois progenitors in the gastrulating embryos [21]. They are downregulated in the mutant cells, supporting the role of PGR in extraembryonic mesoderm differentiation and its function in supporting allantois over hemangioblast specification. In conclusion, we demonstrate that while *Pgr* is dispensable for maintaining the EpiSCs state, it is important for PPS induction [33], and it ultimately plays a critical role in the formation of extraembryonic mesoderm [34].

2.4. PGR Influences the Acquisition of the First Heart Field Fate

Many genes involved in extraembryonic mesoderm differentiation, such as *Hand1*, *Foxf1*, and *Bmp4*, are also important for cardiac differentiation [28,35]. These genes appear to be regulated in a *Pgr*-dependent manner during extraembryonic mesoderm differentiation.

tiation, suggesting a similar role for *Pgr* in regulating the aforementioned genes during cardiac differentiation. Thus, to assess if the lack of PGR affects cardiac differentiation, we establish a differentiation protocol using EpiSCs, initially inducing APS followed by cardiac mesoderm formation (Figure 4A,B). Two progenitor cell types, termed first heart field (FHF) and second heart field (SHF), contribute to the developing heart. The earliest cardiac progenitors that are specified form the FHF and build the left ventricle with a small contribution to the atria. SHF cells arise later and form the right ventricle, atria, and outflow tract [36]. These progenitors are produced in vitro with our differentiation protocol [36,37] (Figure 4B). RNA-seq analysis of WT and Pgr-KO cells confirms that extraembryonic and cardiac mesoderm generated from the mutant cells significantly differs from the WT counterparts (Figure 4C,D). Interestingly, the differentiation of Pgr-KO cells towards cardiac mesoderm clearly favors the SHF-fated cells with cardio-pharyngeal signature identified by the upregulation of *Gata4*, *Nkx2-5*, *Hand2*, *Mef2c*, and *Tbx1* markers [37] (Figure 4E). In contrast, downregulation of Hand1, Foxf1, and Flk1 markers indicates that Pgr-KO cells fail to produce the FHF cardiac progenitors. Of note, the reduction in *Hcn4* and *Tbx3*, which label the heart conductive system progenitors and are FHF derivatives, reiterates PGR's role in FHF specification [38–40]. At the same time, late cardiomyocyte markers such as Myl4, *Myl7*, *Tnnt2*, and *Tnni1* are upregulated in *Pgr-KO* cells (Figure 4E), suggesting that PGR plays a role in the maturation of cardiac muscle cells. Taken together, these data indicate that in addition to its role in extraembryonic mesoderm differentiation, PGR is involved in promoting FHF cell fate and inhibiting SHF progenitor specification.



Figure 4. PGR differentially regulates FHF and SHF cardiac progenitors. (**A**) Schematic illustration of the cardiac mesoderm (CM) differentiation protocol. EpiSCs are initially subjected to APS induction,

and thereafter exposed to BMP for 24 h to induce CM differentiation. (**B**) Heatmap displaying relative expression of selected differentially regulated genes in EpiSCs, APS, and CM (RNA-Seq, $p \le 0.05$, fold-change ≥ 1.5). (**C**) PCA plots clustering WT and *Pgr-KO* cells subjected to differentiation conditions: EpiSCs, PPS, APS, extraembryonic mesoderm (ExM), cardiac mesoderm (CM), and paraxial mesoderm (PM). CM and ExM are affected to a higher extent by *Pgr* depletion. (**D**) MA plots of WT and *Pgr-KO* comparisons in EpiSCs, ExM, CM, and PM showing the highest number of differentially expressed genes in CM and ExM. Blue dots indicate differentially expressed genes with $p \le 0.05$, fold-change ≥ 1.5 (**E**) Differential expression analysis of WT and *Pgr-KO* EpiSCs differentiated towards APS and CM, showing modest effects of loss of *Pgr* on APS induction, but stronger consequences within CM differentiation. In CM, the FHF cardiac markers (*Hand1, Flk1*, and *Foxf1*) are downregulated, while the SHF markers (*Gata4, Nkx2-5, Hand2, Mef2*, and *Tbx1*) are upregulated, revealing a propension of *Pgr-KO* cells to acquire a cardio-pharyngeal fate. First heart field (FHF, ligh pink), second heart field (SHF, blue), late cardiomyocytes (LC, light blue), and heart conductive (HC) makers (pink).

2.5. PGR Modulates Mesoderm Differentiation in an Isoform-Dependent Manner

To further investigate the role of PGR in the specification of the APS and cardiac progenitors, we performed overexpression experiments. PGR exerts its function via two distinct isoforms generated using alternative promoters [41]. PGR-B is a full-length protein, while PGR-A is shorter, lacking the N-terminal transactivation domain [42] (Figure 5A). In addition to common molecular activities in the uterine-derived epithelial cells [1], PGR isoforms were shown to have distinct functions during embryo implantation. To understand which of the PGR isoforms is involved in cardiac specification, we prepared lentiviral overexpression (OE) constructs (Figure 5B). In all three cases (PGR-B OE, PGR-A OE, and PGR-B+A OE), Pgr isoform mRNA levels are at least four-fold higher than control EpiSCs (Figure 5C). Control primers targeting 3'UTR were included to indicate endogenous transcript level. The efficient translation of the OE constructs is confirmed by Western blot (Figure 5D). All three cell lines overexpress the correct protein isoform at higher levels than EpiSCs, APS, and PPS, where PGR has the highest expression levels. The differentiation of PGR-B OE and control EpiSCs towards cardiac mesoderm shows only a mild upregulation of the FHF markers *Hand1*, *Flk1*, and *Foxf1*, indicating that PGR-B could directly or indirectly modulate FHF progenitors (Figure 5E). In contrast, the strongly decreased expression of SHF markers Nkx2-5, Hand2, and Gata4 in cells overexpressing PGR-A indicates that PGR inhibits SHF fate solely or mainly through its short isoform (Figure 5F). In conclusion, we show that PGR modulates cardiac mesoderm differentiation in an isoform-dependent manner.







Figure 5. PRG-B and PGR-A selectively regulate FHF vs. SHF cardiac differentiation. (**A**) Illustration depicting PGR protein structure. The long form of PGR, PGR-B, includes the PGR-B-specific domain (dark red), the DNA-binding domain (yellow), and the ligand-binding domain (light red). The short form of PGR lacks the N-terminal PRG-B domain. (**B**) Schematic of the overexpression assay. The sequences of both full-length PGR-B and shorter PGR-A were cloned into a lentiviral vector under the $EF1\alpha$ promoter. After transduction, cells undergo puromycin selection and differentiation. (**C**) Relative mRNA expression of *Pgr* isoforms measured by RT-qPCR along differentiation of EpiSCs to APS and CM, confirming overexpression of transduced PGR. (**D**) Western blot showing the levels of overexpressed (OE) PGR isoforms in EpiSCs. Overexpression of specific isoforms is higher than the endogenous levels in EpiSC, APS, and PPS. (**E**) RT-qPCR analyses of cells overexpressing PGR isoforms showing mild upregulation of the FHF signature *Hand1*, *Flk1*, and *Foxf1* due to PGR-B overexpression. (**F**) RT-qPCR analyses indicate decreased levels for the SHF signature markers (*Hand2*, *Nkx2-5*, and *Gata4*) by overexpressing PGR-A isoform.

A

2.6. PGR Influences Cell–ECM Interaction and Cytoskeletal Remodeling

Extracellular matrix (ECM) binding, cell adhesion, cytoskeleton remodeling, and cell motility are mechanistic factors strongly influencing PS induction and mesoderm formation [43]. PGR activity was implicated in increasing cell motility and cytoskeletal remodeling [44], suggesting that PGR could control these processes during gastrulation. Indeed, Gene Ontology (GO) enrichment analysis on WT vs. Pgr-KO in PPS cells highlights terms associated with cell adhesion and motility (Figure 6A). RNA-seq data show the altered expression of specific integrins, collagens, and actin-binding proteins, especially in PPS and APS. These proteins are involved in cell migration during PS formation. Interestingly, PS markers such as *T*-*Bra* and *Mixl1* are not strongly impacted, suggesting that changes in adhesion and motility do not alter PS identity in *Pgr-KO* cells. When PS cells are specified into mesoderm progenitors, changes in ECM-cell and cell-cell interactions are essential to generate the physical environment and chemical gradient driving signaling response [45]. RNAseq analysis shows that ECM proteins such as Laminins and Collagens are upregulated in extraembryonic and cardiac mesoderm (Figure 6B), while integrin expression indicates a cell-type-specific pattern, with *ltga3* and *ltga4* differently expressed in extraembryonic mesoderm and cardiac mesoderm, respectively. A comparison of WT and Pgr-KO transcriptional profiles shows changes in laminins and cell-specific integrin expression in the extraembryonic and cardiac mesoderm (Figure 6B). While the majority of integrins are downregulated in Pgr-KO, Itgb3 is specifically upregulated in the extraembryonic mesoderm.

Furthermore, in cardiac mesoderm, Ncam1 [46], the cadherin involved in the cell–cell interactions of atrial and ventricular cells is upregulated. These data suggest that PGR could influence cell differentiation directly or indirectly by selectively modulating the specific mechanisms underlying cell–ECM and cell–cell interactions as well as cytoskeleton remodeling (Figure 6C).

GOMF stats Term name Term ID Pad -l-0gu(pad) _ otal growth factor binding GO.0005102 1382+10 ¹² Image: Comparison of the comparison	SOME statis Generation Term ID Pad -logu(Pad) Image in the indire Image indireImage indire Image indireImage indifitititid Image indireImage indifiti						PPS	APS		ExM	C	M	
GOMF stats Eou ferm name Term ID Padi o -logu(Ppd) stats ignaling receptor binding GO0005102 1.382×10 ⁻¹² Mit. growth factor binding GO0005004 3.254×10 ⁻¹¹ GS settaceIlular matrix binding GO0005001 1.077×10 ⁻⁸ Lata settaceIlular matrix binding GO0005020 1.077×10 ⁻⁸ Lata settaceIlular matrix binding GO0005020 1.077×10 ⁻⁸ Col aminin binding GO0005020 2.070×10 ⁻⁶ GO aminin binding GO0005178 7.347×10 ⁻⁶ GO settoreIbinding GO00005022 2.459×10 ⁻⁵ GO settoreIbinding GO0000502 4.050×10 ⁻⁶ GO settoreIbinding GO0000578 7.347×10 ⁻⁶ GO settoreIbinding GO00005779 4.090×10 ⁻⁵ Itgg Itgg SOBP stats Itgg Itgg Itgg Itgg ferm name Term ID Padi -logu(Ppd) GS Itgg	BOMF stats Erm name Term ID Pad -logo(Pad) st granding receptor binding CO005182 1.382×10 ⁻¹² stratedlular matrix thinding CO005840 2.35×10 ⁻¹¹ stratedlular matrix thinding CO005840 2.35×10 ⁻¹¹ stratedlular matrix thinding CO005840 2.011×10 ⁻¹ stratedlular patrix structural constituent CO005820 2.011×10 ⁻¹ stratedlular patrix structural constituent CO005920 2.011×10 ⁻¹ stratedlular protein binding CO005920 2.015×10 ⁻¹ stratedlular protein binding CO005920 2.05×10 ⁻⁵ structural constituent CO005930 2.05×10 ⁻⁵ struct					W	т ко	WT K	O W	г ко	WT	KO	
GOMF stats T-1 Term name Term ID Pxig -log:s(Ppig) stats signaling receptor binding G0:0005102 1.382×10 ⁺² GS:s growth factor binding G0:0005040 3.254×10 ⁺¹ GS:s extracellular matrix binding G0:0005020 1.077×10 ⁴ GS:s extracellular matrix binding G0:0005020 1.077×10 ⁴ GS:s inhase binding G0:0005020 2.071×10 ⁴ GS:s laminin binding G0:0005078 7.347×10 ⁴ GS:s inheighin binding G0:00005022 2.459×10 ⁵ GS:s stats GO:8P stats Itgg Term name Term ID pxig -logu(pxg) gS	SOMF stats T-Bra ferm name Tem ID P44 -legs(Pp4) Mix:11 ignaling receptor binding GO0005102 1382:101-12 GSc Mix:11 grandsmark GO0005102 1382:101-12 GSc GSc strate-filler matrix binding GO0005201 1077:101-8 GSc GSc strate-filler matrix binding GO0005201 1077:101-8 GSc CO11a1 aminin binding GO0005202 2471:101-8 GSc CO14a5 itemse hinding GO0005226 4.571:101-8 GSc CO14a5 itemse hinding GO0005226 4.571:101-8 GSc CO14a5 itemse hinding GO0005282 2.459:101-5 GSc CO14a6 itemse hinding GO0005292 2.459:10-5 GSc Itgga6 itemse hinding GO0005202 4.56:10-6 GSc Itgga6 item anne Tem ID P44 -legs(Pp4) GSc Itgga7 itgga6 Itgga7 Itgga6 Itgga7 Itgga6 Itgga7 itggs711 GO0000528 1072:1												Eomes
Term name Term ID Padj -logs(Ppd) cts signaling receptor binding GO0005102 1.382×10 ⁻¹² GSSG growth factor binding GO0005004 3.254×10 ⁻¹¹ GSSG extracellular matrix binding GO00050039 2.011×10 ⁻⁴ GSSG integrin binding GO0005023 4.571×10 ⁻⁶ GSG laminin binding GO000002 2.459×10 ⁻⁵ GSG integrin binding GO000002 2.459×10 ⁻⁵ GSG gotskeletal protein binding GO000002 2.459×10 ⁻⁵ GSG GC3P stats stats Itrg Itrg Itrg Term name Term ID pxd -logs(Ppd) stats Itrg	Term name Term ID Pail 0-logu(Pail) St ignaling receptor binding GO0005102 1382-10-12 GSc growth factor binding GO0005888 3.131-10-11 GSc Lamc I stracellular mixing GO00058904 2.252+10-11 GSc Lamc I stracellular mixing GO0005893 2.011-10-4 GSc Col11a1 iname binding GO0005990 2.070-10-5 GSc Col11a1 iname binding GO0005912 2.459-10-5 GSc Col14a5 iterin binding GO000592 2.459-10-5 GSc Col4a65 iterin binding GO000592 2.459-10-5 GSc Itga3 iterin binding GO000592 2.459-10-5 GSc Itga3 iterin binding GO000592 2.459-10-5 GSc Itga6 Itga7 itga6 itga7 itga7 itga6 Itga7 Itga6 Itga7 itga7 itga6 GSc GSc Itga7 Itga6 Itga7 itga7 itga7 Itga6 GSc Itga7 Itga6	GO:MF		stats									T-Bra
signaling receptor binding growth factor binding extracellular matrix binding cell adhesion molecule binding integrin binding integrin binding coords128 integrin binding coords128 integrin binding coords128 coords128 integrin binding coords128 coords	ignaling receptor binding growth factor binding GO 005102 stracellular matrix binding GO 0050840 stracellular matrix binding GO 0050840 stracellular matrix binding GO 0050859 2011×10 ⁴ inase binding GO 0005092 2459×10 ⁵ item aname Term ID pag mame Term ID pag mame Term ID pag mame Term ID pag mame Term ID pag mame Term ID pag mame Term ID pag mame Term ID pag mame terl obiding Souter development Stats	Term name	Term ID	Padj	log ₁₀ (p _{adj}) ≤16	<mark>8</mark>							Mix11
growth factor binding GO.0019838 3.131 × 10 ⁻¹¹ GO.000040 3.254 × 10 ⁻¹¹ GO.000040 3.254 × 10 ⁻¹¹ GO.000040 3.254 × 10 ⁻¹¹ GO.0000201 1.077 × 10 ⁻⁴ GO.0000201 1.077 × 10 ⁻⁴ GO.0000201 1.077 × 10 ⁻⁴ GO.0000201 GO.0000202 2.011 × 10 ⁻⁴ GO.0000201 GO.0000202 2.011 × 10 ⁻⁴ GO.0000202 GO.0000202 2.070 × 10 ⁻⁶ GO.0000202 GO.0000202 2.459 × 10 ⁻⁵ GO.0000202 J.111 × 10 ⁻¹ J.1111 × 10 ⁻	growth factor binding GO.001983 3.131 × 10 ⁻¹¹ Cosc stracellular matrix binding GO.0050840 3.254×10 ⁻¹¹ Lamc.1 stracellular matrix structural constituent GO.0050839 2.011×10 ⁴ Lamc.2 sinase binding GO.0005020 2.070×10 ⁴ Coll1a1 aminin binding GO.000572 2.459×10 ⁴ Coll4a5 stronething GO.000092 2.459×10 ⁴ Coll4a6 stronething GO.000092 2.459×10 ⁵ Itgga3 strine binding GO.000092 2.459×10 ⁵ Itgga7 strast stats Itgga7 Itgga7 strast stats Itggs711 Nccam stats GO.00030154 <td>signaling receptor binding</td> <td>GO:0005102</td> <td>1.382×10⁻¹²</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Geo</td>	signaling receptor binding	GO:0005102	1.382×10 ⁻¹²									Geo
extracellular matrix binding G0.0050840 3.254×10 ⁻¹¹ Image: Second Secon	extracellular matrix binding GO.0050840 3.254×10 ⁻¹¹ 1 107×10 ⁻⁸ 107×10 ⁻⁸ 107×10 ⁻⁸ 107×10 ⁻⁸ 107×10 ⁻⁸ 107×10 ⁻⁸ 10 ⁻¹⁰ 107×10 ⁻⁸ 10 ⁻¹⁰ 107×10 ⁻⁸ 10 ⁻¹⁰	growth factor binding	GO:0019838	3.131×10 ⁻¹¹						_	_		Use
extracellular matrix structural constituent G0.0005201 1.077×10 ⁻⁴ cell adhesion molecule binding G0.00050839 2.011×10 ⁻⁴ integrin binding G0.0001980 2.070×10 ⁻⁶ fibronectin binding G0.0005178 7.347×10 ⁻⁶ fibronectin binding G0.000502 2.459×10 ⁻⁵ actin binding G0.0003779 4.090×10 ⁻⁵ G0.8P term name Term ID p _{xd} -logw(p _{xd}) 10	extracellular matrix structural constituent G0.0005201 1.077×10 ⁻⁸ cli adhesion molecule binding G0.0005089 2.011×10 ⁻⁸ Coll all cinase binding G0.0005202 2.070×10 ⁻⁶ Gold Coll all minin binding G0.0005178 7.347×10 ⁻⁶ Gold Coll all Coll all binonectin binding G0.0005178 7.347×10 ⁻⁶ Gold Coll all Coll all ytoskeletal protein binding G0.0003779 4.090×10 ⁻⁵ Gold Itga3 Itga3 strib binding G0.0003779 4.090×10 ⁻⁵ Gold Itga6 Itga6 SpP stats stats Itga7 Itga6 Itga7 iewelopmental proces G0.0003154 3.864×10 ⁻⁴¹ Gold Itgb3 ell differentiation G0.00032502 4.266×10 ⁻⁵⁶ Gold Itgb3 ell moration G0.0003154 3.864×10 ⁻⁴¹ Gold Itgb3 ell moration G0.0004870 1.448×10 ⁻⁵⁶ Gold Itgb3 ell moration G0.0004777 2.844×10 ⁻⁵⁶ Gold Itgb3 ell moration G0.00	extracellular matrix binding	GO:0050840	3.254×10 ⁻¹¹									Lamc1
cell adhesion molecule binding G0.0050839 2.011×10 ⁴ Coll kinase binding G0.0050839 2.011×10 ⁴ Coll laminih binding G0.001980 2.070×10 ⁴ Coll Coll Coll laminih binding G0.0001983 8.405×10 ⁴ Coll Coll Coll Coll Coll tingen binding G0.0001983 8.405×10 ⁴ Coll Coll <td>sell adhesion molecule binding G0:0050839 2:011×10⁴ Image: Color state Col 1a1 aminin binding G0:0013256 4:571×10⁴ Image: Color state Col 4a5 ibronectin binding G0:0001960 8:405×10⁴ Image: Color state Col 4a6 ytoskeletal protein binding G0:0003779 4:990×10⁵ Image: Color state Ifga3 icosP stats Ifga6 Ifga7 Ifga6 Ifga7 indifferentiation G0:003154 3:864×10⁴¹ Ifga7 Ifgb3 Ifgb3 indifferentiation G0:003154 3:864×10⁴¹ Ifga7 Ifgb3 Ifgb3 indifferentiation G0:003154 3:864×10⁴¹ Ifga7 Ifgb3 Ifgb3 indifferentiation G0:001547 2:804×10⁵⁶ Ifga7 Ifgb3 Ifgb3 id indifferentiation G0:001547 3:864×10⁴¹ Ifga7 Ifgb3 Ifgb3 Ifgb3 Ifga7 ifgirgation G0:001547 2:804×10⁵⁶ Ifga7 Ifgb3 Ifga7 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3<!--</td--><td>extracellular matrix structural constituent</td><td>GO:0005201</td><td>1.077×10⁻⁸</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Lame?</td></td>	sell adhesion molecule binding G0:0050839 2:011×10 ⁴ Image: Color state Col 1a1 aminin binding G0:0013256 4:571×10 ⁴ Image: Color state Col 4a5 ibronectin binding G0:0001960 8:405×10 ⁴ Image: Color state Col 4a6 ytoskeletal protein binding G0:0003779 4:990×10 ⁵ Image: Color state Ifga3 icosP stats Ifga6 Ifga7 Ifga6 Ifga7 indifferentiation G0:003154 3:864×10 ⁴¹ Ifga7 Ifgb3 Ifgb3 indifferentiation G0:003154 3:864×10 ⁴¹ Ifga7 Ifgb3 Ifgb3 indifferentiation G0:003154 3:864×10 ⁴¹ Ifga7 Ifgb3 Ifgb3 indifferentiation G0:001547 2:804×10 ⁵⁶ Ifga7 Ifgb3 Ifgb3 id indifferentiation G0:001547 3:864×10 ⁴¹ Ifga7 Ifgb3 Ifgb3 Ifgb3 Ifga7 ifgirgation G0:001547 2:804×10 ⁵⁶ Ifga7 Ifgb3 Ifga7 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 Ifgb3 </td <td>extracellular matrix structural constituent</td> <td>GO:0005201</td> <td>1.077×10⁻⁸</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Lame?</td>	extracellular matrix structural constituent	GO:0005201	1.077×10 ⁻⁸									Lame?
kinase binding GO001990 2.070×10 ⁻⁶ laminin binding GO00193226 4.571×10 ⁻⁶ lintegrin binding GO0005178 7.347×10 ⁻⁶ cytoskeletal protein binding GO000092 2.459×10 ⁻⁶ actin binding GO0003779 4.090×10 ⁻⁵ GO.8P Term name Term ID p _{xd} -log ₁₀ (p _x d) 15	inase binding aminin binding	cell adhesion molecule binding	GO:0050839	2.011×10 ⁻⁸					_				Lunc2
Iamini binding GO.0043236 4.571×10 ⁻⁶ Col integrin binding GO.0005178 7.347×10 ⁻⁶ Col ibbonetin binding GO.0001968 8.405×10 ⁻⁶ Col cytoskeletal protein binding GO.0003779 4.090×10 ⁻⁵ Ifgg actin binding GO.0003779 4.090×10 ⁻⁵ Ifgg Ifgg GO.8P stats Ifgg Ifgg Ifgg Ifgg Term name Term ID pxg -log ₁₀ (p ₁ g) 1 Ifgg	amini binding 60.0043256 4.571×10 ⁴ 6 the grin binding 60.0005178 7.347×10 ⁶ 6 ibronectin binding 60.0008092 2.459×10 ⁵ 6 ibronectin binding 60.0008092 2.459×10 ⁵ 6 ibronectin binding 60.0003779 4.090×10 ⁵ 7 ibronectin binding 60.0003779 4.090×10 ⁵ 7 ibronectin binding 60.000379 4.090×10 ⁵ 7 ibronectin binding 60.0003154 3.864×10 ⁴¹ 7 ibronectin d cell or subcellular component 60.0003154 3.864×10 ⁴¹ 7 il motility 60.0048870 1.448×10 ³⁶ 7 acculature development 60.0001547 1.240×10 ³⁶ 7 acculature development 60.0001547 1.611×10 ³⁰ 7 acculature development 60.000154 1	kinase binding	GO:0019900	2.070×10 ⁻⁶		5							Collal
integrin binding GO.0005178 7.347×10 ⁻⁶ Col fibronectin binding GO.0001968 8.405×10 ⁻⁶ Col Col cytoskeletal protein binding GO.000092 2.459×10 ⁻⁵ Itgg Itgg Itgg actin binding GO.0003779 4.090×10 ⁻⁵ Itgg Itgg Itgg Itgg GO.8P stats stats Itgg Itgg </td <td>ntegrin binding GO:0005178 7:347×10⁻⁴ http:notetin binding GO:000579 4:090×10⁻⁵ strin binding GO:0003779 4:090×10⁻⁵ 50:8P stats IIga 3 iff ad 4 Ifga 4 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 8 Ifga 8 Ifga 7 Ifga 8 Ifga 7 Ifga 8 Ifga 7 Ifga 7 Ifg</td> <td>laminin binding</td> <td>GO:0043236</td> <td>4.571×10⁻⁶</td> <td></td> <td>B</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Col4a5</td>	ntegrin binding GO:0005178 7:347×10 ⁻⁴ http:notetin binding GO:000579 4:090×10 ⁻⁵ strin binding GO:0003779 4:090×10 ⁻⁵ 50:8P stats IIga 3 iff ad 4 Ifga 4 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 7 Ifga 8 Ifga 8 Ifga 7 Ifga 8 Ifga 7 Ifga 8 Ifga 7 Ifga 7 Ifg	laminin binding	GO:0043236	4.571×10 ⁻⁶		B							Col4a5
fibronectin binding GO.0001968 8.405×10 ⁴ Column cytosketetal protein binding GO.000392 2.459×10 ⁵ Image: Column Ifgg actin binding GO.0003779 4.090×10 ⁵ Image: Column Ifgg Image: Column Ifgg GO.8P stats stats Image: Column Ifgg Image: Column Ifgg Image: Column Ifgg Term name Term ID page -logw(pg) Image: Column Imag	Bibronectin binding GO:0001968 8.405×10.4 Coll4do ytoskeletal protein binding GO:000372 2.459×10.5 Ifga3 strin binding GO:0003779 4.090×10.5 Ifga3 S0:BP stats Ifga7 iewelopmental process GO:0032502 4.286×10.44 iel differentiation GO:003154 3.864×10.41 novement of cell or subcellular component GO:000528 1.072×10 ⁻⁸⁶ ell migration GO:0001647 1.611×10 ³⁰	integrin binding	GO:0005178	7.347×10 ⁻⁶									Caldad
cytoskeletal protein binding GO.0000392 2.459×10 ⁻⁵ Itgg actin binding GO.0003779 4.090×10 ⁻⁵ Itgg Itgg <td>systekeletal protein binding G0:000892 2.459×10⁻⁵ Itga3 schn binding G0:0003779 4.090×10⁻⁵ Itga4 schn binding stats Itga6 Itga7 so:BP stats Itga7 Itga7 imm name Term ID p.sg -logu(p.sg) ct eld differentiation G0:003154 3.864×10⁻⁴¹ Itgs5111 novement G0:000682 1.072×10⁻³⁸ Itgs74 ell migration G0:0016477 2.804×10⁻⁵⁶ Itgs751 ell migration G0:0016477 2.804×10⁻⁵⁶ Itgs75</td> <td>fibranactin hinding</td> <td>60.0001968</td> <td>8.405×10⁻⁶</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td><i>C014a0</i></td>	systekeletal protein binding G0:000892 2.459×10 ⁻⁵ Itga3 schn binding G0:0003779 4.090×10 ⁻⁵ Itga4 schn binding stats Itga6 Itga7 so:BP stats Itga7 Itga7 imm name Term ID p.sg -logu(p.sg) ct eld differentiation G0:003154 3.864×10 ⁻⁴¹ Itgs5111 novement G0:000682 1.072×10 ⁻³⁸ Itgs74 ell migration G0:0016477 2.804×10 ⁻⁵⁶ Itgs751 ell migration G0:0016477 2.804×10 ⁻⁵⁶ Itgs75	fibranactin hinding	60.0001968	8.405×10 ⁻⁶									<i>C014a0</i>
actin binding 60.0003779 4.090×10 ⁻⁵	scin binding G0.0003779 4.090×10 ⁻⁵ Itga4 50:BP stats Itga7 ferm name Term ID pag -logw(pgs) stats ell differentiation G0.0003779 4.286×10 ⁻⁵⁶ Itga7 ell differentiation G0.000376 3.864×10 ⁻⁴¹ Itgb3 ell motility G0.0004870 1.448×10 ⁻⁵⁶ Itga7 ell motility G0.0004870 1.448×10 ⁻⁵⁶ Itga7 ell motility G0.0004870 1.448×10 ⁻⁵⁶ Itga7 asculature development G0.000154 3.864×10 ⁻⁵⁶ Itga7	noronecum binuing	00.0001500										Itan 2
GO.8P stats Term name Term ID Pag g-logs(Ppg) 55	SO.BP stats ierm name Term ID pag o -logac(pag) estimation el differentiation GO.003154 3.864×10 ⁻⁴¹ el motility GO.004870 1.448×10 ⁻³⁶ el motility GO.004870 1.448×10 ⁻³⁶ el motility GO.004870 1.448×10 ⁻³⁶ el motility GO.001547 2.240×10 ³⁶ asculature development GO.000154 1.611×10 ³⁰	cytoskeletal protein binding	GO:0008092	2.459×10 ⁻⁵									ngas
Term name Term ID Pag -log ₁₀ (P _{pd}) -15	Term ID Pagi - log H(Ppg) - stop Iggs 1 Sevelopmental process G0.0032502 4.286×10 ⁻⁶⁴ Iggs 11 Iggs 11 novement of cell or subcellular component G0.0003154 3.864×10 ⁻⁴¹ Iggs 11 Ncam ell motility G0.0004870 1.448×10 ⁻³⁶ Iggs 11 Ncam Iggs 11 ell motility G0.0004870 1.448×10 ⁻³⁶ Iggs 11 Ncam Iggs 12 ell motility G0.0004870 1.448×10 ⁻³⁶ Iggs 11 Iggs 12 Iggs 12 ell motility G0.0004870 1.448×10 ⁻³⁶ Iggs 12 Iggs 12 Iggs 12 ell motility G0.000144 1.611×10 ⁻³⁰ Iggs 12 Iggs 12 Iggs 12	cytoskeletal protein binding actin binding	GO:0008092 GO:0003779	2.459×10 ⁻⁵ 4.090×10 ⁻⁵									ltga4 Itga6
	developmental process GO 0032502 4.286+10 ⁻⁵⁶ Constraint Solution Ncam vell differentiation GO.0030154 3.864×10 ⁻⁴¹ Ncam Ncam novement of cell or subcellular component GO.0004870 1.072×10 ⁻³⁶ MSn ell motility GO.0004870 1.448×10 ⁻³⁶ Ezr asculature development GO.0001944 1.511×10 ³⁰ GSn	cytoskeltal protein binding actin binding GO:8P	GO:0008092 GO:0003779	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats	-	lesion				i,	5		ltga4 Itga6 Itga7 Itgb3
developmental process 60:0032502 4.286×10 ⁵⁶	Bill differentiation GO.0030154 3.864×10 ⁴¹ NCCam novement of cell or subcellular component GO.000528 1.072×10 ³⁸ MSn ell motility GO.0048870 1.448×10 ³⁶ MSn ell migration GO.001647 2.804×10 ³⁶ Ezr sculature development GO.001944 1.611×10 ³⁰ GSn	cytoskeletal protein binding cytoskeletal protein binding actin binding GO:BP Term name	G0:000892 G0:0003779	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats		Adhesion				l			Itga4 Itga6 Itga7 Itgb3 Igsf11
cell differentiation GO:0030154 3.864×10 ⁴¹	novement of cell or subcellular component GO.0006928 1.072×10 ⁻³⁸ Image: Component of cell or subcellular component MSR xell motility GO.00064870 1.448×10 ⁻³⁶ Image: Component of cell or subcellular component MSR ell migration GO.00016477 2.804×10 ⁻³⁶ Image: Component of cell or subcellular component Image: Component of cell or subcell	cytoskeletal protein binding cytoskeletal protein binding actin binding GO:BP Term name developmental process	G0.000892 G0.0003779 Term ID G0.0035502	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Padj 4.286×10 ⁻⁵⁶		Adhesion			l	l			ltga4 Itga6 Itga7 Itgb3 Igsf11 Noam
movement of cell or subcellular component 60:0006928 1.072×10 ³⁸	xell motility GO.0048870 1.448×10 ⁻³⁶ Ear rell migration GO.0016477 2.804×10 ⁻³⁶ Ezr asculature development GO.0001944 1.611×10 ⁻³⁰ GSn	cytoskeletal protein binding cytoskeletal protein binding actin binding GO:BP Term name developmental process cell differentiation	G0.000892 G0.000892 G0.0003779 Term ID G0.0032502 G0.003154	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Padj 4.286×10 ⁻⁵⁶ 3.864×10 ⁻⁴¹	0 -log ₁₀ (p ₄ d) 416	Adhesion				l			ltga4 Itga6 Itga7 Itgb3 Igsf11 Ncam
cell motility GC:0048870 1.448×10 ⁻³⁶	xell migration GO.0016477 2.804×10 ⁻³⁶ P EZF EZF asculature development GO.0001944 1.611×10 ⁻³⁰ F GSN GSN	cycloskeletal protein binding cycloskeletal protein binding actin binding GC:BP Term name developmental process cell differentiation movement of cell or subcellular component	G0:0006992 G0:000892 G0:0003779	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Paij 4.286×10 ⁻⁵⁶ 3.864×10 ⁻⁴¹ 1.072×10 ⁻³⁸		g Adhesion				6			ltga4 Itga6 Itga7 Itgb3 Igsf11 Ncam Msn
cell migration GO.0016477 2.804×10 ⁻³⁶	asculature development GO.0001944 1.611×10 ⁻³⁰	cycloskeletal protein binding cycloskeletal protein binding actin binding GO:BP Term name developmental process cell differentiation movement of cell or subcellular component cell motility	G0:000892 G0:000892 G0:0003779 Term ID G0:0032502 G0:003154 G0:0030154 G0:0008928 G0:0004870	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Paig 4.286×10 ⁻⁵⁶ 3.864×10 ⁻⁴¹ 1.072×10 ⁻³⁸ 1.448×10 ⁻³⁶	e -log ₁₀ (p ₄ cj)c(6	Adhesion							ltga5 Itga4 Itga6 Itga7 Itgb3 Igsf11 Ncam Msn Err
		GO-BP GO-BP GO-BP GO-BP GO-BP Geventation Geveentation Geventation Geveentation Geveentat	G0:000892 G0:000892 G0:0003779	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats P _{246j} 4.286×10 ⁻⁵⁶ 3.864×10 ⁻⁴¹ 1.07×10 ⁻³⁸ 1.48×10 ⁻³⁶ 2.804×10 ⁻³⁶		odelling Adhesion							ltga3 Itga4 Itga6 Itga7 Itgb3 Igsf11 Ncam Msn Ezr
vasculature development GO:0001944 1.611×10 **	xell adhesion GO:0007155 1.652×10 ³⁰	GO-BP GO-BP Term name developmental process cell differentiation movement of cell or subcellular component cell motility cell migration vasculature development	G0:000892 G0:000892 G0:0003779	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Pagi 4.286×10 ⁻⁵⁶ 3.864×10 ⁻⁴¹ 1.072×10 ⁻³⁸ 2.804×10 ⁻³⁶ 2.804×10 ⁻³⁶ 1.611×10 ⁻³⁰		emodelling Adhesion				ļ			liga5 liga4 liga6 liga7 ligb3 lgsf11 Ncam Msn Ezr Gsn
Cell adhesion GC/0007155 1.652×10 ⁻³⁰ The Th		cytoskeletal protein binding cytoskeletal protein binding actin binding GO.8P Term name developmental process cell differentiation movement of cell or subcellular component cell motility cell migration vasculature development cell adhesion	G0.0006992 G0.0003779 G0.0003779 G0.0032502 G0.0039502 G0.0039154 G0.0006928 G0.0048870 G0.0016477 G0.0001944 G0.0007155	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Paij 4.286×10 ⁻⁵⁵ 3.864×10 ⁻⁴¹ 1.072×10 ⁻³⁸ 1.448×10 ⁻³⁶ 2.804×10 ⁻³⁶ 2.804×10 ⁻³⁶ 1.612×10 ⁻³⁰		n Remodelling Adhesion							liga5 liga4 liga6 liga7 ligb3 lgsf11 Ncam Msn Ezr Gsn Tmsh4x
Vasculature development GC0001944 1.611×10 ⁻¹ cell adhesion GC0007155 1.652×10 ³⁰	ell surface receptor signaling pathway GO:0007166 4.392×10 ²⁶	Active and an analog cycloskeletal protein binding actin binding GO:BP Term name developmental process cell differentiation movement of cell or subcellular component cell motility cell migration vasculature development cell surface receptor signaling pathway	G0.0006992 G0.0003779 G0.0003779 G0.0003502 G0.0030154 G0.0030154 G0.0048870 G0.0048870 G0.0016477 G0.0001944 G0.000155 G0.000156	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Paij 4.286×10 ⁻⁵⁵ 3.864×10 ⁻⁴¹ 1.072×10 ⁻³⁸ 1.448×10 ⁻³⁶ 2.804×10 ⁻³⁶ 1.611×10 ⁻³⁰ 4.392×10 ⁻²⁸		Adhesion Adhesion							ltga5 Itga4 Itga6 Itga7 Itgb3 Igsf11 Ncam Msn Ezr Gsn Tmsb4x
vascuadure development GOUDU1944 1.611×10 ⁻¹⁴	11113042	GO.8P GO.8P GO.8P GO.8P Go.8P Go.8P Go.8P Go.8D	G0:00092 G0:00092 G0:0003779	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Padj 4.286×10 ⁻⁵⁶ 3.864×10 ⁻⁴¹ 1.072×10 ⁻³⁸ 1.612×10 ⁻³⁶ 2.804×10 ⁻³⁶ 1.611×10 ⁻³⁰ 1.652×10 ⁻³⁰		tin Remodelling Adhesion							liga5 liga4 liga6 liga7 ligb3 lgsf11 Ncam Msn Ezr Gsn Tmsb4x
vasculature development GC/00/1944 1.611×10 ⁻¹ The cell adhesion GC/0007155 1.652×10 ⁻³⁶ The cell-sell adhesion GC/0007166 4.392×10 ⁻³⁶ The	xell surface receptor signaling pathway GO.0007166 4.392×10 ⁻²⁶	Active and binding cyctoskeletal protein binding actin binding GO.BP Term name developmental process cell differentiation movement of cell or subcellular component cell motility cell migration vasculature development cell adhesion cell-subface receptor signaling pathway cell-cell action	G0:000192 G0:000092 G0:0003779 G0:0032502 G0:0032502 G0:0032502 G0:0039154 G0:0001948 G0:0001944 G0:0001955 G0:0001155 G0:0001155 G0:0000155	2.459×10 ⁻⁵ 4.090×10 ⁻⁵ stats Paij 4.286×10 ⁻⁵⁶ 3.864×10 ⁻⁵⁶ 3.864×10 ⁻⁴¹ 1.072×10 ⁻³⁸ 1.614×10 ⁻³⁶ 2.804×10 ⁻³⁵ 1.611×10 ⁻³⁰ 1.652×10 ⁻³⁰ 1.652×10 ⁻²⁰ 1.88×10 ⁻⁷⁷		Actin Remodelling Adhesion							liga3 liga4 liga6 liga7 ligb3 lgsf11 Ncam Msn Ezr Gsn Tmsb4x Sdc3

Figure 6. Cont.



Figure 6. PGR influences cell-ECM, cell-cell interactions and cytoskeletal remodeling of mesoderm progenitors. (**A**) GO-term enrichment analysis of genes differentially expressed in WT and *Pgr-KO* PPS displays significant overrepresentation of terms associated with ECM interactions, cell adhesion, and cytoskeletal protein binding (Fisher's exact test with Bonferroni correction). (**B**) Heatmap indicating downregulation of Laminins, Collagens, and actin remodeling transcripts in APS and PPS with moderate changes in the PS signature genes. In ExM and CM, adhesion and ECM genes are downregulated in *Pgr-KO*, with the exception of *Itgb3*, which is specifically upregulated in the ExM and *Ncam*1, which is upregulated in CM. (**C**) *PGR-KO* cells show altered expression of genes related to cellular adhesion, cytoskeleton remodeling, and ECM composition. Changes in the cellular interactions with the direct environment alter the differentiation program and affect the balanced production of mesoderm types.

3. Discussion

The importance of progesterone signaling in preparing and supporting pregnancy as well as maintaining ovulation is well-documented [2,18,20,47,48]. Recently, it was also reported that PGR supports in vitro development of murine pre-implantation blastocysts [6].

We reported that, in vivo, PGR is expressed in the PS of gastrulating mouse embryos in a posterior-to-anterior gradient, and enriched in primed pluripotent stem cells, EpiSCs, which represent the cellular state preceding gastrulation. In vitro, during EpiSCs differentiation towards mesoderm, both the transcript and protein peak in a 24 h window, which coincides with the high expression of the PS marker *T-Bra*, supporting a potential role in mesoderm differentiation.

Here, we report that PGR is involved in regulating extraembryonic and cardiac mesoderm differentiation. We show that PGR has a lineage-specific effect on the maturation of extraembryonic mesodermal progenitors, promoting hemangioblast differentiation over allantois fate.

Additionally, during cardiac differentiation, PGR promotes the expression of the FHF markers *Hand1* and *Foxf1*, as well as *Hcn4* and *Tbx3*, which label the heart conductive progenitors, suggesting that it could support the formation of atrial and ventricular cardiomyocytes with FHF origin. Interestingly, PGR has an opposite effect on SHF cardiac genes, inhibiting the expression of *Hand2*, *Mef2c*, *Myl4*, *Myl7*, *Tnnt2*, and *Tnni1*. These results suggest that PGR promotes the differentiation of FHF derivatives and represses SHF fate. While *Pgr* mutant embryos do not have evident cardiac defects, it is possible that an alternative hormonal receptor compensatory mechanism exists in vivo. Another possibility

is that SHF-derived cells could rescue the FHF deficiency. In zebrafish embryos, ablation experiments showed that SHF could compensate for the absence of FHF [49].

The observation that the in vitro phenotype is more severe in *Pgr-KO* cells exposed to differentiation conditions towards extraembryonic and cardiac mesoderm that rely on BMP signaling suggests that PGR modulates BMP-driven mesoderm specification. The posterior-anterior gradient of PGR in the embryos also resembles BMP levels at gastrulation, supporting a possible BMP-PGR interaction. It has previously been reported that BMP signaling upregulates PGR expression in the uterus. Similarly, BMP could induce PGR in the posterior PS [50]. Therefore, specification of FHF progenitors could be mediated by a BMP-PGR driven mechanism, with SHF arising from cells exposed to a lower level of BMP and PGR. Strikingly, it has been shown previously that high BMP activity is required to induce *Gata4* and *Nkx2-5* expression at E8.0, but not for their maintenance, and that the BMP receptor is crucial for the specification of the FHF. SHF progenitor differentiation instead strongly relies on canonical WNT signaling [51]. Moreover, it was reported that with in vitro differentiation models, BMP signaling directly activates the transcription of *Id1*, which is critical for the cardiac induction of FHF genes [52]. On the contrary, SHF genes are not subject to ID1-BMP-mediated regulation, supporting the hypothesis that FHF and SHF have different requirement for BMP and PGR. In another context, progesterone and BMP have previously been associated as inducers of branching morphogenesis in epithelial mammary cells [53].

The dual role of PGR as cardiac progenitor modulator is clearer in the overexpression experiments. While overexpression of PGR has a moderate effect on FHF markers, it has, on the contrary, a strong effect on SHF, suggesting that PGR blocks SHF progenitors if present at higher levels. We can speculate the existence of a BMP-dependent safe-lock mechanism blocking premature SHF differentiation or transdifferentiation and sustaining concomitantly the FHF progenitor pool. To work as a safeguard of premature differentiation could be the major role of PGR, and it could explain why the *Pgr* mutant mice do not have strong cardiac defects.

FHF cells mostly become cardiomyocytes, while SHF-derived cells are multipotent and give rise to various cardiac cell types, such as cardiomyocytes, smooth muscle, endothelial, and fibroblast cells. In adult mice, it was reported that progesterone has an anti-atherosclerotic effect and inhibits proliferation and migration of aortic smooth muscle cells [54,55]. Thus, PGR could have an inhibitory effect on cardiac muscle cells originating from the SHF⁵⁷. Again postnatally, progesterone supplementation promotes neonatal cardiomyocytes proliferation through the upregulation of YAP signaling [56]. Thus, PGR could promote cardiomyocyte formation.

Mesoderm delamination from the epiblast requires basal membrane disruption, apical constriction, loss of apicobasal polarity, changes in cytoskeletal properties, and acquisition of cell motility. Thus, after exiting pluripotent epiblast state, the different mesodermal populations acquire a specific set of cytoskeletal components necessary for cell motility and adhesion, which can underlie the differences in their migratory properties. A recent study showed that during mouse gastrulation, extraembryonic and embryonic mesoderm showed differences in cell migratory properties [57]. ExM and embryonic mesodermal cells have distinct shapes, cytoskeletal composition, and migration dynamics that might play a role in determining their ultimate fate [58]. We found that integrins *Itga3* and *Itga4* are specifically expressed in extraembryonic and cardiac mesoderm, respectively, indicating that specific cell-matrix interactions could differentially affect their migratory and differentiation properties. Integrins can signal across the plasma membrane in both directions, transducing extracellular and intracellular signals affecting cell fate [58]. ITGB3 mediates the cross-talk between cells and the stromal microenvironment in different contexts by direct interaction with fibronectin and focal adhesion proteins but also by vesicle-based intercellular communication [59]. In Pgr mutant cells, the upregulation of *Itgb3* in ExM suggest that a PGR-ITGB3-dependent mechanism could mediate the establishment of a specific microenvironment promoting extraembryonic mesoderm differentiation. ITGB3 is

historically associated with hemangioblast differentiation, and its upregulation coincides with increased levels of *Tal1* and *Gata2*, thereby indicating a shift of *Pgr-KO* ExM cells towards a hemangioblast fate [60]. These data suggest that acquisition of the mesodermal state correlates with ECM interaction and the establishment of a microenvironment that mediates specific cell responses and differentiation.

Altogether, the observed phenotypes could be attributed to the previously described PGR–cSRC interaction [24]. The perturbation within the PGR–cSRC network could alter the downstream PI3K/AKT and MAPK signaling pathways affecting proliferation and differentiation, or the JNK, RhoA, and FAK cascade influencing cell motility and adhesion (Figure 6C). As a consequence, changes in adhesion properties and ECM composition could lead to the reshaping of the cellular niche, thereby indirectly influencing cell fate (Figure 6C). Therefore, PGR could act as a BMP-induced modulator of cell fate through c-SRC, fine-tuning and amplifying the response to FGF and thereby generating a gradient of response (Figure 7A,B).

In other contexts, PGR is known to directly affect cytoskeleton actin dynamics and focal adhesion formation in breast cancer, ovarian, neural, and human endothelial cells. Furthermore, previous reports showed that progesterone is involved in cytoskeletal remodeling and cell migration during gastrulation in zebrafish embryos [61]. While this study focused mainly on the ligand and enzymes involved in its synthesis, we demonstrated that during gastrulation, progesterone signaling exerts its function primarily through its receptor. PGR indeed affects the expression of genes related to cell adhesion and microtubule dynamics.

The PGR protein exists in at least two isoforms—a longer PGR-B and an N-terminally truncated PGR-A [41,42]. The balance of the PGR isoforms is important to promote the transition into partuition. PGR-A overexpression induces smooth muscle contractility of the uterus [62]. Similarly, during cardiac mesoderm specification, different PGR isoform activity could indicate a specific requirement in contractility of FHF and SHF cardiomyocytes. Notably, we show that while PGR-B mildly modulates the expression of FHF markers, PGR-A has a major effect inhibiting SHF genes. We also report that its absence promotes differentiation towards hemangioblast and SHF fates, and that these functions are carried out in an isoform-dependent manner. These data indicate that the alternative isoforms exhibit overlapping and distinct functions in the different mesodermal progenitors.

Progesterone and its synthetic analogues are used as contraceptive agents [62] and a treatment for recurring early miscarriages [63]. Our work in mouse and cell models shows that PGR is essential not only for embryo implantation but also for embryonic development, thus further emphasizing its significance during pregnancy supporting embryonic life. Moreover, our work suggests monitoring progesterone administration during early pregnancy so as not to impact embryonic heart development negatively.

The potential impact of this study, however, extends beyond the consequences for embryonic development. Stem-cell-based therapies are considered to be one of the possible groundbreaking solutions for degenerative diseases such as type 1 diabetes, Parkinson's, and heart failure, as they can be differentiated into virtually any somatic cell type [64–66]. Although great progress is being made in this field, differentiation protocols require further improvements to produce uniform populations of desired cells with high efficiencies. Our study sheds some light on the mechanisms involved in mesoderm development, focusing specifically on cardiac fate commitment and shows that the level of progesterone in the cell culture medium could be one of the factors influencing in vitro differentiation.



Figure 7. BMP-induced PGR expression fine-tunes and amplifies FGF response during cell specification. (**A**) Illustration showing a proposed molecular mechanism of PGR function during differentiation. As described previously, BMP induces PGR upregulation [50]. PGR, in turn, interacts with c-SRC [24] and activates its downstream targets: PI3K, MAPK, JNK, RHOA and FAK, thus influencing cell survival, differentiation, proliferation, adhesion, and motility. (**B**) Illustration depicting ligand gradients described in the gastrulating mouse embryo at around E6.5 with BMP expressed in posterior–anterior gradient and modulating the expression of PGR along the same axis. We propose that this PGR gradient establishes a gradient for FGF response in the early mouse embryo, as shown in A, thus influencing cell fate decisions during mesoderm development, specifically ExM and CM specification.

4. Materials and Methods

Unless stated otherwise, all chemical reagents were purchased from Sigma Aldrich, all cell culture reagents from Thermo Fisher Scientific (Waltham, MA, USA), and all the cytokines from Qkine (Milton, Cambridge, UK).

4.1. Cell Culture

A total of 129 EpiSCs were cultured on fibronectin-coated plates (15 μ g/mL; Merck Millipore (Burlington, MA, USA), FC01015) in N2B27 supplemented with 20 ng/mL Activin A Plus, 10 ng/mL bFGF and 1 μ M XAV939 (EpiSC medium). N2B27 was prepared in the following way: 200 mL DMEM:F12, 200 mL Neurobasal Medium, 4 mL L-Glutamine, 400 μ L β -mercaptoethanol, 2 mL N2 supplement, and 4 mL B27 supplement. N2 reagent was prepared by adding 10 mL 7.5% BSA to 68.75 mL DMEM:F12, mixing well, and adding the following components drop-wise: 250 mg insulin re-suspended in 10 mL 0.01 HCl, 1 g apo-transferrin dissolved in 10 mL MilliQ water, 330 μ L progesterone (stock solution 0.6 mg/mL), 1 mL putrescine (stock solution 160 ng/mL), and 100 μ L Na selenite (stock solution 3 mM). Mouse embryonic stem cells (mESCs) were cultured on gelatin-coated plates in N2B27 medium supplemented with LIF, 1 μ M PD-0325901, and 3 μ M CHIR99021. As part of standard cell culture procedure, all cell lines were mycoplasma-tested and confirmed to have normal karyotype.

4.2. EpiSC Differentiation to PS and Mesoderm Progenitors

Cells were differentiated in a monolayer and seeded on fibronectin-coated wells at 10.5×10^3 cells/cm² in chemically defined EpiSC medium 24 h prior to induction of differentiation. PPS cells were induced by supplementing N2B27 with 30 ng/mL Activin A, 40 ng/mL BMP4, 6 μ M CHIR-99021, 20 ng/mL bFGF, and 100 nM PIK-90, while APS cells induction medium consisted of N2B27 with 30 ng/mL Activin A, 4 μ M CHIR-99021, 20 ng/mL bFGF, and 100 nM PIK-90. In both cases, cells were cultured in the appropriate media for 24 h. PPS cells were further differentiated to extraembryonic mesoderm (ExM) for another 24 h by supplementing N2B27 with 1 μ M A-83-01, 30 ng/mL BMP4, and 1 μ M C59. Lateral mesoderm (LM) was obtained by applying the ExM medium on APS cells for 24 h, and finally paraxial mesoderm (PM) was induced from APS with N2B27 supplemented with 1 μ M A-83-01, 3 μ M CHIR-99021, 250 nM LDN193189, and 20 ng/mL bFGF for 24 h.

4.3. RT-qPCR

Cells were washed once with PBS and detached from the culture dish using Accutase. The cells were collected, and RNA was extracted using QIAGEN RNeasy Mini Kit (Qiagen, 74106, Hilden, Germany) according to the manufacturer's instructions. A total of 1 μ g of RNA was reverse transcribed using SuperScript III enzyme (Thermo Fisher Scientific, 18080-044) and random hexamers (Thermo Fisher Scientific, N8080127), according to the producer's protocol. All qPCR experiments were run on Roche LightCycler480 Real-Time PCR System using SYBR Green master mix (Roche, 04707516001, Basel, Switzerland). A mix of concentrated cDNA was used as a standard curve, two housekeeping genes (*Tbp* and *Sdha*) were used for normalization, and all samples were run in duplicates. The list of primer sequences can be found in Supplementary Table S2.

4.4. Western Blot

Cells were washed once with cold PBS on ice and scraped in Laemmli buffer. Cells were sonicated at 20% for 10 s to release the protein content using Branson Digital Sonifier Model S-450D (Marshall Scientific), centrifuged at maximum speed for 10 min at 4 °C, and stored at -80 °C until the gel could be run. The protein concentration was measured on NanoDrop (Thermo Fisher Scientific) A280, and 25–30 µg of total protein was loaded in each lane, diluted in Laemmli for the final volume of 30 µL with 2 µL 0.1 M DTT and 3 µL loading dye (0.01% (w/v) bromophenol blue). We ran the samples in NuPAGE Novex 4–12% Bis-Tris Protein Gels (Thermo Fisher Scientific, NP0321BOX) using 1× NuPAGE MES SDS running buffer (Thermo Fisher Scientific, NP0002) at 150 V for 70 min. We transferred the protein to Amersham Protran Nitrocellulose Blotting membrane 0.45 µm (GE Healthcare, 10600003, Chicago, IL, USA) in 1× NuPAGE transfer buffer (Thermo Fisher Scientific, NP0006) at 100 V for 1.5 h in a cold room. Membranes were shortly rinsed in PBS and blocked using 5% skim milk in PBS with 0.1% Tween-20 for 1 h at room temperature (RT) and next incubated

with primary antibodies at dilution 1:1000 overnight at 4 °C. For blotting PGR, we used Progesterone Receptor A/B (D8Q2J) XP[®] Rabbit mAb (Cell Signaling, 8757, Danvers, MA, USA). The following day, membranes were washed 3×10 min with 0.1% Tween-20 in PBS and incubated with HRP-conjugated secondary antibodies for 2 h at RT (donkey anti-Rabbit HRP (Thermo Fisher Scientific, A16023, 1:10,000)). Finally, the membranes were washed as previously, and the bands were visualized using Amersham ECL Prime Western Blotting Detection reagent (GE Healthcare, RPN2236) and ChemiDoc MP (Bio-Rad).

4.5. Immunofluorescence and Imaging

Cells were seeded on iBidi plates (ibidi, 8-well tissue culture treated #80826) at a density of 10–20 k cells/well, and fixed 24–48 h afterwards using 4% PFA for 15 min at RT. Next, we permeabilized the cells using 0.5% Triton in PBS for 10 min at RT and blocked the non-specific binding sites using 3% BSA in 0.1% Triton/PBS for 20 min at RT. We incubated cells with primary antibody solution (1% BSA in 0.1% Triton/PBS with antibodies) containing mouse anti-PGR (Santa Cruz Biotechnology, sc-810, Dallas, TX, USA) overnight at 4 °C. The following day, we washed cells 3 × 5 min using washing solution (1% BSA in 0.1% Triton/PBS) and incubated with fluorophore-conjugated secondary antibodies and nuclear dye DAPI in darkness for 2 h at RT. Finally, we washed the cells 3 × 5 min in washing solution and 1 × 5 min in PBS. The cells were either immediately imaged or stored at 4 °C and imaged within 1 month.

Mouse embryos were dissected and fixed in 4% PFA at RT for 30 min at RT. They were permeabilized using PBS/PVP + 1% (v/v) Triton X-100 for 10 min at RT, shaking. Embryos were blocked overnight at 4 °C in CAS-Block (Thermo Fisher Scientific, 008120). Embryos were incubated with the 1:100 diluted primary antibodies for 48 h at 4 °C, and the following antibodies were used: mouse anti-PGR (Santa Cruz Biotechnology, sc-810), goat anti-SOX2 (R&D Systems, AF2018, Minneapolis, MN, USA), and rabbit anti-BRACHYURY (R&D Systems, MAB20851). Embryos were washed 3 x 10 min with CAS-Block and then overnight at 4 °C. Next, they were incubated with secondary antibodies for 24 h in 4 °C. Embryos were washed 3 × 10 min in CAS-Block and then overnight at 4 °C. Afterwards, they were incubated with 1 µg/mL DAPI for 1 h at RT. Finally, embryos were washed 3 × 10 min at RT and dehydrated in ascending concentrations of methanol, eventually reaching 100%. Embryos were imaged using Leica TCS SP8 confocal microscope, and the images were analyzed using ImarisTM software (v9.3.0, Oxford Instruments, Abingdon, UK).

4.6. scRNA-Seq

Massively Parallel Single-Cell RNA-Sequencing technology (MARS-Seq) was performed for scRNA-Seq. EpiSCs were seeded at a density of 60 k cells per well of a six-well cell culture plate pre-coated with $15 \,\mu g/mL$ human Fibronectin and differentiated to PPS and ExM according to differentiation protocols described above. At 24 h and 48 h timepoints, cells were dissociated using Accutase for 3 min at 37 °C and counted. A total of 0.5×10^6 cells per condition were washed with ice-cold FACS buffer (10% (v/v) FBS in PBS) and resuspended in 1 mL ice-cold FACS buffer containing 1 µg/mL DAPI. Single cells were sorted into Eppendorf Polypropylene U-shaped 384-well Twin Tec PCR Microplates (Thermo Fisher Scientific, 10573035) containing 2 µL of lysis solution (0.2% (v/v) Triton X-100) supplemented with 0.4 U/ μ L RNasin Ribonuclease Inhibitor (Promega, N2515, Madison, WI, USA) and 400 nM indexed RT primer from group 1 (1–96 barcodes) or group 2 (97–192 barcodes). Wild-type (WT) EpiSCs were sorted into each plate, as spike-in control for batch-effect correction. Capture plates were prepared on the Bravo automated liquid handling robot station (Agilent, Santa Clara, CA, USA) using 384-filtered tips (Agilent, 19133-142). Index sorting was performed using a FACS Aria III cell sorter (BD Biosciences, San Jose, CA, USA) at the DanStem Flow Cytometry Platform (University of Copenhagen, Copenhagen, Denmark), sorting singlets and live cells only. Directly after sorting, plates were briefly centrifuged, snap-frozen on dry ice, and stored at -80 °C for

further procedures. Semi-automated library preparation was carried out using 10–12 total cycles of PCR amplification and AMPure XP beads (Beckman Coulter Life Sciences, A63881, Indianapolis, IN, USA).

DNA concentration was measured with a Qubit Fluorometer (Thermo Fisher Scientific, Q32854) and fragment size was determined with a Fragment analyzer (Agilent). Libraries were paired-end sequenced on a Next-Seq 500 Sequencer (Illumina, San Diego, CA, USA) at the DanStem Genomics Platform (University of Copenhagen, Copenhagen, Denmark). Between 1146 and 1528 cells were sequenced per lane.

Data for PPS can be retrieved under the following accession number E-MTAB-12106, and the data for ExM under E-MTAB-12107.

4.7. Bulk RNA-Seq

EpiSCs were seeded at 60 k cells/well in six-well cell culture plates pre-coated with $15 \mu g/mL$ human Fibronectin and differentiated to PPS, APS, ExM, LM, and PM as described above. At chosen time points (either 24 h or 48 h), cells were lysed, and total RNA was extracted using the QIAGEN RNeasy Mini Kit according to the manufacturer's instructions (Qiagen, 74106). RNA concentration was quantified by NanoDrop, and quality was verified with a Fragment analyzer. Library preparation was carried out using 0.5 μ g of RNA with NEBNext Ultra II RNA library Prep Kit (New England BioLabs, E7770S, Ipswich, MA, USA) according to the manufacturer's instructions. Libraries were amplified for 4 total PCR cycles and purified with AMPure XP beads. DNA concentration was measured with a Qubit Fluorometer, and fragment size was determined with a Fragment analyzer. All samples were sequenced in biological triplicates on a Next-Seq 500 Sequencer (Illumina) at the DanStem Genomics Platform (University of Copenhagen, Copenhagen, Denmark).

Bulk RNA-seq data can be accessed on ArrayExpress under E-MTAB-12104 accession number.

4.8. Cloning of the Overexpression Vectors and Lentiviral Packaging

RNA was extracted from WT EpiSCs using QIAGEN RNeasy Mini Kit (Qiagen, 74106), and 1 μ g was reverse transcribed using SuperScript III enzyme (Thermo Fisher Scientific, 18080-044) and random hexamers (Thermo Fisher Scientific, N8080127) according to the manufacturer's protocol. We PCR amplified *Pgr* sequences corresponding to isoforms A and B using the following primers:

PGR-B forward: 5' CACC-ATGACTGAGCTGCAGGCAAAG 3'

PGR-B reverse: 5' TCACTTTTTGTGAAAGAGGAGCGG 3'

PGR-A forward: 5' CACC-ATGAGTCGGCCAGAGATCAAG 3'

PGR-A reverse: 5' TCACTTTTTGTGAAAGAGGAGCG 3'.

We ran the PCR product on 1.5% agarose gel and extracted the DNA from gel using QIAquick Gel Extraction Kit (Qiagen, 28706). Purified PCR product was cloned into pENTRTM/D-TOPOTM (Thermo Fisher Scientific, K240020) vector using TOP10TM chemically competent *E. coli*, which was part of the kit, according to the producer's protocol. We then used GatewayTM LR ClonaseTM Enzyme mix (Thermo Fisher Scientific, 11791019) and, following the manufacturer's protocol, cloned the sequences encoding the two isoforms into destination vector pLEX307 (kindly provided by the Helin laboratory). The resulting constructs carrying the sequences encoding either PGR-A or PGR-B were verified by sequencing.

To prepare lentiviral vectors, HEK293T cells were seeded on 10 cm plastic cell culture dishes at a density of 6×10^6 cells/dish. The following day cells were transfected using the following mix for each 10 cm dish: 15 µg pLEX307-PgrA or pLEX-PgrB, 10 µg packaging plasmid psPAX2, and 5 µg envelope-encoding pCMV-VSV-G with 90 µL 10 mg/mL PEI (1:3, DNA:PEI) in 500 µL Opti-MEMTM reduced serum medium (Thermo Fisher Scientific, 31985062). Transfection was performed in the late afternoon and medium was changed the following morning. Medium was collected 24 h and 48 h later for virus concentration. The virus was concentrated using Amicon[®] Ultra 15 mL Centrifugal Filters (Merck Millipore,

UFC900324). Briefly, collected medium was centrifuged for 15 min at maximum speed to remove cellular debris. Supernatant was loaded on the Amicon[®] Ultra 15 mL Centrifugal Filters and centrifuged at maximum speed for 15–20 min. The loading of the media and centrifugation was repeated until all the virus-containing medium was passed through the filter and concentrated to 500–1000 μ L total volume. The concentrated virus was stored in -80 °C for up to one year.

4.9. Isoform-Specific PGR Overexpression during Differentiation

Cells were seeded on fibronectin-coated 6-well plates at a density of 100 k cells/well in the appropriate culture media. The following day cells were transduced at MOI > 0.7, and the following day medium was changed to EpiSC medium containing 1 μ g/mL puromycin (Sigma Aldrich, P8833, Saint Louis, MO, USA). The selection pressure was maintained for the following two days, when the cells were passaged and seeded for differentiation experiment on 6-well plates at a density 100 k cells/well. The following day medium was changed to differentiation medium. Cell lysates were collected 24 h and 48 h after induction of mesoderm differentiation for the analysis.

4.10. Cell Lines Genotyping and Karyotyping

Cell lines were genotyped using GoTaq[®] Green Master Mix (Promega, M7122). At least 10 ng of gDNA was used for each PCR reaction. The product of the reaction was run on 2% agarose gel, and the resulting bands were imaged using ChemiDoc MP (Bio-Rad). For karyotyping cells were sent to Cell Guidance Systems, Cambridge, UK.

4.11. Mice

All animals used in this study were maintained in laboratory animal housing facilities at macroenvironmental temperature and humidity ranges of 20–24 °C and 45–65%, respectively, with a 12/12 h light/dark cycle. All animal work was carried out in accordance with European legislation. All work was authorized by and carried out under the Project License 2017-15-0201-01255 issued by the Danish Regulatory Authority. Mouse embryos were dissected at stages E6.5-7.5, with the stage described as E6.75 dissected in the evening.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms231810307/s1. Reference [67] has been cited in the Supplementary Materials.

Author Contributions: A.M.D. and E.F. conceived, performed, and analyzed the experiments. X.G. and L.M. performed and analyzed the scRNA sequencing. V.G., N.A.M. and A.M.D. performed and analyzed the bulk RNA sequencing. A.M.D. performed the lentiviral experiments, the immunofluorescence and the RT-qPCR. A.M.D. generated the *Pgr-KO* EpiSC cell lines. L.M., X.G., N.A.M., V.G. and E.F. prepared the figures and wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study is supported by the Novo Nordisk Foundation grant number NNF17CC0027852 to E.F. and by Novo Nordisk Foundation Bioscience Ph.D. Fellowship grant number NNF17CC0026756 to A.M.D.

Institutional Review Board Statement: All animal work was carried out in accordance with European legislation. All work was authorised by and carried out under the Project License 2017-15-0201-01255 issued by the Danish Regulatory Authority.

Informed Consent Statement: Not applicable, the study did not involve humans.

Data Availability Statement: The data is available under the following accession numbers on Array-Express: E-MTAB-12104 (RNAseq data for WT and *Pgr-KO* cells), E-MTAB-12106 (scRNA-seq for PPS), E-MTAB-12107 (scRNA-seq for ExM). **Acknowledgments:** We thank the staff of the DanStem Core Facilities: H.M. Neil, M. Michaut, G. De la Cruz, P. van Dieken, J.M. Bulkescher, A. Shrestha, M. Paulsen and E. Fernandez-Rebollo. We are grateful to M.M. Rothová for sharing the wild-type 129 EpiSC line, K. Helin for providing the overexpression plasmid backbone, and the Core Facility for Transgenic Mice at the University of Copenhagen, especially J. Martin Gonzalez.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Li, R.; Wang, X.; Huang, Z.; Balaji, J.; Kim, T.H.; Wang, T.; Zhou, L.; Deleon, A.; Cook, M.E.; Marbrey, M.W.; et al. The role of epithelial progesterone receptor isoforms in embryo implantation. *iScience* **2021**, *24*, 103487. [CrossRef] [PubMed]
- 2. Graham, J.D.; Clarke, C.L. Physiological Action of Progesterone in Target Tissues. Endocr. Rev. 1997, 18, 502–519. [CrossRef]
- Olbrich, L.; Wessel, L.; Balakrishnan-Renuka, A.; Böing, M.; Brand-Saberi, B.; Theiss, C. Rapid Impact of Progesterone on the Neuronal Growth Cone. *Endocrinology* 2013, 154, 3784–3795. [CrossRef] [PubMed]
- Sim, C.B.; Phipson, B.; Ziemann, M.; Rafehi, H.; Mills, R.J.; Watt, K.I.; Abu-Bonsrah, K.D.; Kalathur, R.K.; Voges, H.K.; Dinh, D.T.; et al. Sex-Specific Control of Human Heart Maturation by the Progesterone Receptor. *Circulation* 2021, 143, 1614–1628. [CrossRef] [PubMed]
- Kot, A.; Zhong, Z.A.; Zhang, H.L.; Lay, Y.-A.E.; ELane, N.; Yao, W. Sex dimorphic regulation of osteoprogenitor progesterone in bone stromal cells. J. Mol. Endocrinol. 2017, 59, 351–363. [CrossRef] [PubMed]
- 6. Zhang, C.; Murphy, B.D. Progesterone is critical for the development of mouse embryos. *Endocrine* 2014, 46, 615–623. [CrossRef]
- Arnold, S.J.; Robertson, E.J. Making a commitment: Cell lineage allocation and axis patterning in the early mouse embryo. *Nat. Rev. Mol. Cell Biol.* 2009, 10, 91–103. [CrossRef] [PubMed]
- 8. Ferretti, E.; Hadjantonakis, A.-K. Mesoderm specification and diversification: From single cells to emergent tissues. *Curr. Opin. Cell Biol.* **2019**, *61*, 110–116. [CrossRef]
- Kinder, S.; Tsang, T.; Quinlan, G.; Hadjantonakis, A.; Nagy, A.; Tam, P. The orderly allocation of mesodermal cells to the extraembryonic structures and the anteroposterior axis during gastrulation of the mouse embryo. *Development* 1999, 126, 4691–4701. [CrossRef] [PubMed]
- Brons, I.G.M.; Smithers, L.E.; Trotter, M.W.B.; Rugg-Gunn, P.; Sun, B.; de Sousa Lopes, S.M.C.; Howlett, S.K.; Clarkson, A.; Ahrlund-Richter, L.; Pedersen, R.A.; et al. Derivation of pluripotent epiblast stem cells from mammalian embryos. *Nat. Cell Biol.* 2007, 448, 191–195. [CrossRef]
- Tesar, P.J.; Chenoweth, J.G.; Brook, F.A.; Davies, T.J.; Evans, E.P.; Mack, D.L.; Gardner, R.L.; McKay, R.D.G. New cell lines from mouse epiblast share defining features with human embryonic stem cells. *Nature* 2007, 448, 196–199. [CrossRef] [PubMed]
- 12. Pfister, S.; Steiner, K.A.; Tam, P.P. Gene expression pattern and progression of embryogenesis in the immediate post-implantation period of mouse development. *Gene Expr. Patterns* **2007**, *7*, 558–573. [CrossRef] [PubMed]
- Najm, F.J.; Chenoweth, J.G.; Anderson, P.D.; Nadeau, J.H.; Redline, R.W.; McKay, R.D.; Tesar, P.J. Isolation of Epiblast Stem Cells from Preimplantation Mouse Embryos. Cell Stem Cell 2011, 8, 318–325. [CrossRef]
- 14. Morgani, S.; Nichols, J.; Hadjantonakis, A.-K. The many faces of Pluripotency: In vitro adaptations of a continuum of in vivo states. *BMC Dev. Biol.* **2017**, *17*, 7. [CrossRef] [PubMed]
- Osteil, P.; Studdert, J.B.; Goh, H.N.; Wilkie, E.E.; Fan, X.; Khoo, P.-L.; Peng, G.; Salehin, N.; Knowles, H.; Han, J.-D.J.; et al. Dynamics of Wnt activity on the acquisition of ectoderm potency in epiblast stem cells. *Development* 2019, 146, dev172858. [CrossRef] [PubMed]
- Hagan, C.R.; Lange, C.A. Molecular determinants of context-dependent progesterone receptor action in breast cancer. *BMC Med.* 2014, 12, 32. [CrossRef] [PubMed]
- Werner, L.R.; Gibson, K.A.; Goodman, M.L.; Helm, D.E.; Walter, K.R.; Holloran, S.M.; Trinca, G.M.; Hastings, R.C.; Yang, H.H.; Hu, Y.; et al. Progesterone promotes immunomodulation and tumor development in the murine mammary gland. *J. Immunother. Cancer* 2021, 9, e001710. [CrossRef]
- 18. Kim, J.J.; Kurita, T.; Bulun, S.E. Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer. *Endocr. Rev.* 2013, *34*, 130–162. [CrossRef] [PubMed]
- Marquardt, R.M.; Kim, T.H.; Shin, J.-H.; Jeong, J.-W. Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis? *Int. J. Mol. Sci.* 2019, 20, 3822. [CrossRef] [PubMed]
- Gebril, M.; Hirota, Y.; Aikawa, S.; Fukui, Y.; Kaku, T.; Matsuo, M.; Hirata, T.; Akaeda, S.; Hiraoka, T.; Shimizu-Hirota, R.; et al. Uterine Epithelial Progesterone Receptor Governs Uterine Receptivity Through Epithelial Cell Differentiation. *Endocrinology* 2020, 161, bqaa195. [CrossRef] [PubMed]
- Pijuan-Sala, B.; Griffiths, J.; Guibentif, C.; Hiscock, T.; Jawaid, W.; Calero-Nieto, F.; Mulas, C.; Ibarra-Soria, X.; Tyser, R.C.V.; Ho, D.L.L.; et al. A single-cell molecular map of mouse gastrulation and early organogenesis. *Nature* 2019, 566, 490–495. [CrossRef]
- 22. Wilkinson, D.; Bhatt, S.; Herrmann, B.G. Expression pattern of the mouse T gene and its role in mesoderm formation. *Nature* **1990**, 343, 657–659. [CrossRef]
- Perrot-Applanat, M.; Lescop, P.; Milgrom, E. The cytoskeleton and the cellular traffic of the progesterone receptor. *J. Cell Biol.* 1992, 119, 337–348. [CrossRef] [PubMed]

- Boonyaratanakornkit, V.; Scott, M.P.; Ribon, V.; Sherman, L.; Anderson, S.M.; Maller, J.L.; Miller, W.; Edwards, D.P. Progesterone Receptor Contains a Proline-Rich Motif that Directly Interacts with SH3 Domains and Activates c-Src Family Tyrosine Kinases. *Mol. Cell* 2001, *8*, 269–280. [CrossRef]
- Rivera-Pérez, J.A.; Magnuson, T. Primitive streak formation in mice is preceded by localized activation of Brachyury and Wnt3. Dev. Biol. 2005, 288, 363–371. [CrossRef] [PubMed]
- 26. Chazaud, C.; Yamanaka, Y. Lineage specification in the mouse preimplantation embryo. *Development* **2016**, *143*, 1063–1074. [CrossRef]
- 27. Morikawa, Y.; Cserjesi, P. Extra-embryonic vasculature development is regulated by the transcription factor HAND1. *Development* **2004**, *131*, 2195–2204. [CrossRef]
- 28. Mahlapuu, M.; Ormestad, M.; Enerback, S.; Carlsson, P. The forkhead transcription factor Foxf1 is required for differentiation of extra-embryonic and lateral plate mesoderm. *Development* 2001, *128*, 155–166. [CrossRef]
- 29. Ghimire, S.; Van Der Jeught, M.; Neupane, J.; Roost, M.S.; Anckaert, J.; Popovic, M.; Van Nieuwerburgh, F.; Mestdagh, P.; Vandesompele, J.; Deforce, D.; et al. Comparative analysis of naive, primed and ground state pluripotency in mouse embryonic stem cells originating from the same genetic background. *Sci. Rep.* **2018**, *8*, 5884. [CrossRef]
- Barnes, R.M.; Firulli, B.A.; Conway, S.J.; Vincentz, J.W.; Firulli, A.B. Analysis of the Hand1 cell lineage reveals novel contributions to cardiovascular, neural crest, extra-embryonic, and lateral mesoderm derivatives. *Dev. Dyn.* 2010, 239, 3086–3097. [CrossRef] [PubMed]
- Qiu, C.; Cao, J.; Martin, B.K.; Li, T.; Welsh, I.C.; Srivatsan, S.; Huang, X.; Calderon, D.; Noble, W.S.; Disteche, C.M.; et al. Systematic reconstruction of cellular trajectories across mouse embryogenesis. *Nat. Genet.* 2022, 54, 328–341. [CrossRef]
- 32. Xiong, J.-W. Molecular and developmental biology of the hemangioblast. Dev. Dyn. 2008, 237, 1218–1231. [CrossRef] [PubMed]
- 33. Winnier, G.; Blessing, M.; Labosky, P.A.; Hogan, B.L. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes Dev.* **1995**, *9*, 2105–2116. [CrossRef]
- Fujiwara, T.; Dunn, N.R.; Hogan, B.L.M. Bone morphogenetic protein 4 in the extraembryonic mesoderm is required for allantois development and the localization and survival of primordial germ cells in the mouse. *Proc. Natl. Acad. Sci. USA* 2001, 98, 13739–13744. [CrossRef]
- 35. Firulli, A.B.; McFadden, D.G.; Lin, Q.; Srivastava, D.; Olson, E.N. Heart and extra-embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1. *Nat. Genet.* **1998**, *18*, 266–270. [CrossRef] [PubMed]
- Kelly, R.G.; Buckingham, M.E.; Moorman, A.F. Heart Fields and Cardiac Morphogenesis. Cold Spring Harb. Perspect. Med. 2014, 4, a015750. [CrossRef]
- 37. Rossi, G.; Broguiere, N.; Miyamoto, M.; Boni, A.; Guiet, R.; Girgin, M.; Kelly, R.G.; Kwon, C.; Lutolf, M.P. Capturing Cardiogenesis in Gastruloids. *Cell Stem Cell* **2021**, *28*, 230–240.e6. [CrossRef]
- Herrmann, F.; Bundschu, K.; Kühl, S.J.; Kühl, M. Tbx5 overexpression favors a first heart field lineage in murine embryonic stem cells and in Xenopus laevis embryos. *Dev. Dyn.* 2011, 240, 2634–2645. [CrossRef]
- Später, D.; Abramczuk, M.K.; Buac, K.; Zangi, L.; Stachel, M.W.; Clarke, J.; Sahara, M.; Ludwig, A.; Chien, K.R. A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells. *Nat. Cell Biol.* 2013, 15, 1098–1106. [CrossRef] [PubMed]
- Bakker, M.L.; Boukens, B.J.; Mommersteeg, M.T.; Brons, J.F.; Wakker, V.; Moorman, A.F.; Christoffels, V.M. Transcription Factor Tbx3 Is Required for the Specification of the Atrioventricular Conduction System. *Circ. Res.* 2008, 102, 1340–1349. [CrossRef] [PubMed]
- 41. Kastner, P.; Krust, A.; Turcotte, B.; Stropp, U.; Tora, L.; Gronemeyer, H.; Chambon, P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. *EMBO J.* **1990**, *9*, 1603–1614. [CrossRef]
- Sartorius, C.A.; Melville, M.Y.; Hovland, A.R.; Takimoto, G.S.; Horwitz, K.B.; Tung, L. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. *Mol. Endocrinol.* 1994, *8*, 1347–1360. [CrossRef] [PubMed]
- 43. Rivera-Pérez, J.A.; Hadjantonakis, A.-K. The Dynamics of Morphogenesis in the Early Mouse Embryo. *Cold Spring Harb. Perspect. Biol.* **2014**, *7*, a015867. [CrossRef]
- Cheng, L.; Pricolo, V.; Biancani, P.; Behar, J. Overexpression of progesterone receptor B increases sensitivity of human colon muscle cells to progesterone. *Am. J. Physiol. Liver Physiol.* 2008, 295, G493–G502. [CrossRef] [PubMed]
- Piccolo, S.; Sladitschek-Martens, H.L.; Cordenonsi, M. Mechanosignaling in vertebrate development. *Dev. Biol.* 2022, 488, 54–67. [CrossRef] [PubMed]
- 46. Burroughs, C. Distribution of the neural cell adhesion molecule (NCAM) during heart development. *J. Mol. Cell. Cardiol.* **1991**, 23, 1411–1422. [CrossRef]
- Guennoun, R. Progesterone in the Brain: Hormone, Neurosteroid and Neuroprotectant. Int. J. Mol. Sci. 2020, 21, 5271. [CrossRef] [PubMed]
- Bishop, C.V.; Hennebold, J.D.; Kahl, C.A.; Stouffer, R.L. Knockdown of Progesterone Receptor (PGR) in Macaque Granulosa Cells Disrupts Ovulation and Progesterone Production. *Biol. Reprod.* 2016, 94, 109. [CrossRef]

- Sánchez-Iranzo, H.; Galardi-Castilla, M.; Minguillón, C.; Sanz-Morejón, A.; González-Rosa, J.M.; Felker, A.; Ernst, A.; Guzmán-Martínez, G.; Mosimann, C.; Mercader, N. Tbx5a lineage tracing shows cardiomyocyte plasticity during zebrafish heart regeneration. *Nat. Commun.* 2018, *9*, 428. [CrossRef] [PubMed]
- Clementi, C.; Tripurani, S.K.; Large, M.J.; Edson, M.A.; Creighton, C.J.; Hawkins, S.M.; Kovanci, E.; Kaartinen, V.; Lydon, J.P.; Pangas, S.A.; et al. Activin-Like Kinase 2 Functions in Peri-implantation Uterine Signaling in Mice and Humans. *PLoS Genet.* 2013, 9, e1003863. [CrossRef] [PubMed]
- Klaus, A.; Saga, Y.; Taketo, M.M.; Tzahor, E.; Birchmeier, W. Distinct roles of Wnt/β-catenin and Bmp signaling during early cardiogenesis. Proc. Natl. Acad. Sci. USA 2007, 104, 18531–18536. [CrossRef] [PubMed]
- 52. Klaus, A.; Müller, M.; Schulz, H.; Saga, Y.; Martin, J.F.; Birchmeier, W. Wnt/β-catenin and Bmp signals control distinct sets of transcription factors in cardiac progenitor cells. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 10921–10926. [CrossRef]
- Satoh, K.; Hovey, R.C.; Malewski, T.; Warri, A.; Goldhar, A.S.; Ginsburg, E.; Saito, K.; Lydon, J.P.; Vonderhaar, B.K. Progesterone enhances branching morphogenesis in the mouse mammary gland by increased expression of Msx2. *Oncogene* 2007, 26, 7526–7534. [CrossRef] [PubMed]
- 54. Wang, H.-C.; Lee, W.-S. Progesterone-Induced Migration Inhibition in Male Rat Aortic Smooth Muscle Cells Through the cSrc/AKT/ERK 2/p38 Pathway-Mediated Up-Regulation of p27. *Endocrinology* **2014**, *155*, 1428–1435. [CrossRef] [PubMed]
- Sawada, H.; Rateri, D.L.; Moorleghen, J.J.; Majesky, M.W.; Daugherty, A. Smooth Muscle Cells Derived From Second Heart Field and Cardiac Neural Crest Reside in Spatially Distinct Domains in the Media of the Ascending Aorta—Brief Report. *Arter. Thromb. Vasc. Biol.* 2017, 37, 1722–1726. [CrossRef]
- 56. Lan, C.; Cao, N.; Chen, C.; Qu, S.; Fan, C.; Luo, H.; Zeng, A.; Yu, C.; Xue, Y.; Ren, H.; et al. Progesterone, via yes-associated protein, promotes cardiomyocyte proliferation and cardiac repair. *Cell Prolif.* **2020**, *53*, e12910. [CrossRef]
- 57. Saykali, B.; Mathiah, N.; Nahaboo, W.; Racu, M.-L.; Hammou, L.; Defrance, M.; Migeotte, I. Distinct mesoderm migration phenotypes in extra-embryonic and embryonic regions of the early mouse embryo. *eLife* **2019**, *8*, e42434. [CrossRef] [PubMed]
- 58. Hynes, R.O. Integrins: Bidirectional, Allosteric Signaling Machines. Cell 2002, 110, 673–687. [CrossRef]
- 59. Zhu, C.; Kong, Z.; Wang, B.; Cheng, W.; Wu, A.; Meng, X. ITGB3/CD61: A hub modulator and target in the tumor microenvironment. *Am. J. Transl. Res.* **2019**, *11*, 7195–7208.
- Huang, K.; Gao, J.; Du, J.; Ma, N.; Zhu, Y.; Wu, P.; Zhang, T.; Wang, W.; Li, Y.; Chen, Q.; et al. Generation and Analysis of GATA2 w/eGFP Human ESCs Reveal ITGB3/CD61 as a Reliable Marker for Defining Hemogenic Endothelial Cells during Hematopoiesis. *Stem Cell Rep.* 2016, 7, 854–868. [CrossRef]
- 61. Eckerle, S.; Ringler, M.; Lecaudey, V.; Nitschke, R.; Driever, W. Progesterone modulates microtubule dynamics and epiboly progression during zebrafish gastrulation. *Dev. Biol.* **2017**, *434*, 249–266. [CrossRef] [PubMed]
- Peavey, M.C.; Wu, S.-P.; Li, R.; Liu, J.; Emery, O.M.; Wang, T.; Zhou, L.; Wetendorf, M.; Yallampalli, C.; Gibbons, W.E.; et al. Progesterone receptor isoform B regulates the *Oxtr-Plcl2-Trpc3* pathway to suppress uterine contractility. *Proc. Natl. Acad. Sci.* USA 2021, 118, e2011643118. [CrossRef]
- Coomarasamy, A.; Gallos, I.D.; Papadopoulou, A.; Dhillon-Smith, R.K.; Al-Memar, M.; Brewin, J.; Christiansen, O.B.; Stephenson, M.D.; Oladapo, O.T.; Wijeyaratne, C.N.; et al. Sporadic miscarriage: Evidence to provide effective care. *Lancet* 2021, 397, 1668–1674. [CrossRef]
- 64. Kim, S.W.; Woo, H.-J.; Kim, E.H.; Kim, H.S.; Na Suh, H.; Kim, S.-H.; Song, J.-J.; Wulansari, N.; Kang, M.; Choi, S.-Y.; et al. Neural stem cells derived from human midbrain organoids as a stable source for treating Parkinson's disease: Midbrain organoid-NSCs (Og-NSC) as a stable source for PD treatment. *Prog. Neurobiol.* **2021**, 204, 102086. [CrossRef]
- Siehler, J.; Blöchinger, A.K.; Meier, M.; Lickert, H. Engineering islets from stem cells for advanced therapies of diabetes. *Nat. Rev. Drug Discov.* 2021, 20, 920–940. [CrossRef] [PubMed]
- 66. Ai, X.; Yan, B.; Witman, N.; Gong, Y.; Yang, L.; Tan, Y.; Chen, Y.; Liu, M.; Lu, T.; Luo, R.; et al. Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI. *Mol. Ther.* **2022**, *in press*. [CrossRef]
- Sugimoto, M.; Kondo, M.; Koga, Y.; Shiura, H.; Ikeda, R.; Hirose, M.; Ogura, A.; Murakami, A.; Yoshiki, A.; Chuva de Sousa Lopes, S.M.; et al. A simple and robust method for establishing homogeneous mouse epiblast stem cell lines by wnt inhibition. *Stem Cell Rep.* 2015, 4, 744–757. [CrossRef] [PubMed]